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ABSTRACT OF THE DISSERTATION
Identification of Prognostic Cancer Biomarkers through the Application of RNA-Seq
Technologies and Bioinformatics
by
Nathan William Wong
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2017
Dr. Xiaowei Wang, Chair
MicroRNAs (miRNAs) are short single-stranded RNAs that function as the guide sequence of
the post-transcriptional regulatory process known as the RNA-induced silencing complex
(RISC), which targets mRNA sequences for degradation through complementary binding to the
guide miRNA. Changes in miRNA expression have been reported as correlated with numerous
biological processes, including embryonic development, cellular differentiation, and disease
manifestation. In the latter case, dysregulation has been observed in response to infection by
human papillomavirus (HPV), which has also been established as both oncogenic in cervical
cancers and oropharyngeal cancers and favorable for overall patient survival after tumor
formation. The identification of dysregulated miRNAs associated with both HPV infection and
cancer survival requires large datasets of high-throughput sequencing data, which were obtained
through The Cancer Genome Atlas. By analyzing this public data, we have identified a series of
proposed mechanisms for cancer formation and survival that is mediated through the miRNARISC regulatory mechanism in response to HPV infection. We have also identified a diverse set
of miRNA biomarkers that have been incorporated into linear expression-based risk signatures
that are prognostic for overall patient survival after tumor diagnosis in HPV-related cancers. The
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tools that were used to identify both miRNA biomarkers and proposed targets in public datasets,
such as The Cancer Genome Atlas, have since been incorporated into an web-accessible
resource, OncomiR.org, to streamline the process of biomarker identification for the cancer
research community.
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Chapter 1: Introduction
The expanded role of RNA-sequencing platforms in the identification of cancer
biomarkers has allowed for the research community to delve deeply into the genomic
mechanisms behind tumor formation and survival, and subsequently identify coding and
noncoding nucleotide sequences that can be applied to the clinical setting in determining patient
risk of tumor formation and survival. Here, we will describe bioinformatics techniques and
pipelines that have been applied to next-generation RNA-sequencing data used to identify such
biomarkers, and various mechanisms that may be affected by the dysregulated biomarkers in
tumor tissues.

1.1

Biomarkers in Contemporary Personalized Medicine
Medicine has always consisted of two primary facets: the identification of an ailment

based on presented symptoms, and the treatment of said ailment. In modern times, the two
aspects have begun to overlap as the paradigm of personalized medicine has taken form. It is rare
that two patients present with identical symptoms, due to variations in environment, behavior,
and genetics; as such, therapies should be tailored as well, so as to maximize treatment efficacy.
This has taken a number of different forms including the identification of specific therapeutic
targets, the expansion of diagnostic criteria, and the intersection of the two fields.
The field of biomarker identification can also be separated into these two categories.
Certain biomarkers can be utilized in the clinical setting to stratify patients by risk of disease
development or progression. Comparatively, the identification of markers that can be acted upon
therapeutically, either through drugs or other interventions, constitute the second category.
Biomarkers can serve as both therapeutic interventions and diagnostic criteria. One of the better
known examples is in the contemporary treatment of breast cancer. Upon presentation, a tumor
1

sample can be tested for three different cell surface receptors: estrogen receptor (ER),
progesterone receptor (PR) and human epidermal growth factor receptor (HER2/neu, or HER2)
(1). Breast cancer cells may express these markers at a significantly higher level than the
surrounding healthy cells, as well as being crucial for tumor proliferation, making the markers
strong candidates for intervention. The standard chemotherapeutic approach for ER/PR(+), also
called hormone-positive, breast cancer is hormone therapy, which attacks the signaling pathway
controlled by the receptors. One mechanism of preventing the receptor-mediated signaling
cascade is through competitive inhibition, in which the drug competes with estrogen for binding
to the receptor; such drugs include tamoxifen (trade name Nolvadex) and toremifene (Farestan),
which modulate binding of estrogen through competition for the receptor, and fulvestrant
(Faslodex), which destabilizes the receptor after binding to induce receptor degradation (2,3).
Another approach is the reduction of estrogen available to activate the receptor signaling
pathway, which can be achieved by preventing its production in the ovaries or through aromatase
inhibitors, such as anastrozole (Arimidex), which prevent the aromatase enzyme from producing
estrogen (4). HER2(+) breast cancers can be treated with monoclonal antibodies (mAbs) such as
trastuzumab (Herceptin) and pertuzumab (Perjeta) (5,6). HER2 is an EGF receptor that initiates
signaling in the MAPK, PI3K/Akt, and STAT pathways, among others, leading to cell
proliferation (7). By targeting HER2, tumor growth and cellular replication can be arrested;
additionally, some evidence suggests that trastuzumab also can activate the anti-proliferative
protein p27 (8). It should also be noted that breast cancers may also test negative for all three
markers, which constitutes a small but high-risk cohort of cancers which are candidates for more
drastic interventions (9).

2

Diagnostic criteria in the clinic has typically included samples that can be easily observed
or obtained from the patient through minimally invasive procedures; for example, prostatespecific antigen, a biomarker that can indicate the development of prostate cancer, can be
isolated from a blood draw (10). However, such diagnostic tests can be imprecise in determining
risk; the same warning holds true for evaluating behavioral and environmental risk factors such
as smoking and alcohol consumption or exposure to high risk carcinogens. Additional
environmental factors to consider can include the presence of foreign bodies such as viruses.
Evidence has shown that certain viruses, including the Epstein-Barr virus, human
papillomavirus, and hepatitis viruses B and C, are tumorigenic agents (11). As such, behavioral
factors such as sexual practices may need to be considered by the diagnostician, since certain
activities increase the likelihood of patient exposure.
Precision for risk stratification can be improved through genotyping, which has become
increasingly more affordable in recent years, as evidenced by home genotyping test distributed
by companies such as 23andMe (12). Diagnostic genomic markers can include protein-coding
genes, which can be observed and measured at the proteomic level through procedures like in
situ hybridization, the method used to identify the previously described markers for breast
cancer. Genomic biomarkers can also include noncoding RNA sequences which can be shorter
than 50 bases (e.g. microRNAs and PIWI-interacting RNAs) or as long as coding genes (e.g.
large intergenic noncoding RNAs and circular RNAs) (13,14). Historically, noncoding RNA
sequences were considered “junk” RNA, as they did not fit into the classical dogma of molecular
biology, i.e. DNA is transcribed to RNA, which is translated to proteins (13). Relatively recently,
some noncoding RNA species have been shown to be have a greater purpose; for example,
microRNAs serve an important role in post-transcriptional regulation, which will be described
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later in this chapter in greater detail (15). Similar to protein-coding transcripts, noncoding
transcripts may also be dysregulated in tumor tissues when compared to normal tissues, or even
when comparing between poor and fair patient prognosis. Given the regulatory implications of
some of these RNA species, their biological effects may be as drastic as a typical protein
regulatory element.
The improved accessibility of genomic and sequencing platforms has also allowed for
large-scale genomic studies for the characterization of various cancers. In 2004, the National
Cancer Institute and the National Human Genome Research Institute launched a nationwide pilot
program titled “The Cancer Genome Atlas” (TCGA) to perform such analyses on cancers of
significant clinical interest (16). By pooling patient tumor samples from multiple treatment
centers throughout North America, geographical bias could be eliminated in identifying
tumorigenic and relevant clinical features. Additionally, TCGA was designed to provide a central
data repository for both raw and processed data. The first publication from TCGA provided
insights into the genetic makeup of glioblastoma that confirmed previous observations as well as
identified novel tumor characteristics (17). Similar analyses were conducted on 32 other cancer
types, including more common cancer species like breast, head and neck, and cervical cancers,
and less common but higher risk types such as adrenocortical carcinoma and mesothelioma (16).
The diversity of analysis types include whole genome sequencing, RNA-sequencing, short RNAsequencing (also described as miRNA-sequencing), and methylation analysis (16). By providing
both the raw and the processed data, the research community has access to a large dataset of
genomic data that can be mined for diagnostic and therapeutic biomarkers in a wide variety of
cancer types.

4

Biomarker identification requires large datasets such as those made available by TCGA,
so as to identify significant features that standout from the background. The process of
identifying said biomarkers, as well as their biological relevance requires an understanding of
bioinformatics, which utilizes statistical analysis for biological data. In this dissertation, I will be
presenting the methods and principles of applying bioinformatics for the identification of
transcript-based biomarkers in HPV-related cancers, and future directions for the clinical
application of the results of this research.

1.2

MicroRNAs: History and Functions in Biological Processes

and Diseases
1.2.1 MicroRNA Discovery, Biogenesis, and Function
MicroRNAs (miRNAs) are short (~22 nucleotide) single-stranded RNA sequences that
function within the post-transcriptional regulatory process known as RNA interference (RNAi).
MicroRNAs were first described in 1993 in the nematode Caenorhabditis elegans, when the
single-stranded 22nt long gene lin-4 was determined to regulate expression of the developmental
gene lin-14 through complementary binding in the 3’ untranslated region (3’UTR) (18,19). A
later study identified the developmentally miRNA let-7 in C. elegans, which was found to also
be conserved in multiple species, including Homo sapiens, indicating that microRNAs and their
regulatory effects were not limited to nematodes (20,21). In the years since, miRNAs have been
identified in 223 species, with 2588 high-confidence mature miRNA sequences in humans alone
(22).
The biogenesis of microRNAs has been extensively reviewed by Ha and Kim (23).
Canonically, after initial transcription by RNA-polymerase II, the pri-miRNA is processed
5
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Figure 1.1: miRNA biogenesis and function. The miRNA gene is transcribed by RNA polymerase II
[1] into the pri-miRNA, which is cleaved by the Drosha/DGCR8 complex to form the pre-miRNA
hairpin structure [2]. The pre-miRNA is transported from the nucleus to the cytoplasm by exportin
5/RAN-GTP [3-4]. The hairpin is cleaved by Dicer [5] before the paired miRNA strands loaded into
the Argonaute proteins [6]. HSP90 helps remove the passenger strand, resulting in the mature
miRNA silencing complex [7], which can bind to the 3’UTR of target sequences and induce
transcript degradation [8]. Image adapted from Ha and Kim (23).

within the nucleus by the Drosha-DGCR8 complex into the hairpin-shaped stem-loop premiRNA. The pre-miRNA is then exported to the cytoplasm by means of a transport complex
comprised of exportin 5 and RAN-GTP. Once in the cytoplasm, the pre-miRNA is cleaved by
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Dicer near the terminal loop, resulting in a small RNA duplex. The resulting strands form the 3p
and 5p species of the mature miRNA. The duplex is loaded into the Argonaute RNA-induced
silencing complex (RISC) with the aid of the HSP90 protein, after which the passenger strand is
removed (24). The RISC is then guided to messenger RNA strands and prevents translation
through inhibition or degradation of the target transcript (15,25) (Figure 1.1).

1.2.2 Prediction of MicroRNA Targets
The selection of target mRNA sequences is driven primarily by complementary matching
of bases 2-8 of the miRNA, or its seed sequence, to regions of the 3’UTR, which suggests that
miRNAs are able to modulate the expression of multiple gene targets. This particular
characteristic of miRNA-target interactions has driven the research community to identify likely
miRNA-target pairings and additional distinguishing attributes, starting with TargetScan in 2005
(26). As initially developed as a standalone package by the Bartel group, TargetScan
implemented the seed match as the primary factor in defining miRNA targets, and scored each
potential target interaction based on the Gibbs free energy of the binding site; subsequent score
ranking was used to define a cutoff that maximized signal-to-noise ratio (27). This first iteration
identified species conservation as a strong contributing factor, as the ratio was increased when
miRNA-target interactions were identified in the three species used for model training: humans,
mice, and pufferfish. The second version of TargetScan, which accompanied the launch of the
TargetScan web database, confirmed species conservation as a significant feature by expanding
the training cohort to five vertebrate species, including dogs, chickens, and rats, but removing
pufferfish. Subsequent editions built on this framework included features such as supplementary
binding sites, target location in the 3’UTR, and GC content, as well as identifying potential
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compensatory mechanisms for non-canonical (i.e. not based on seed-complementarity) binding,
including target site abundance (28-30)
. The latest version, released in 2015, adds fourteen distinct feature which further account
for non-canonical binding, and implemented step-wise regression based on the Akaike
information criterion (AIC), which characterizes data loss within models (31).
Although TargetScan is one of the better-known miRNA prediction algorithms, it is by
far not the only one available to the research community. Additional resources have been
created, including DIANA-microT, miRanda, RNA22, and MirTarget, which incorporate a
variety of bioinformatics techniques to determine necessary and supplemental features in
microRNA targeting (32-35). DIANA-microT also used stepwise-regression based on the AIC in
2012 to identify features used in non-canonical binding. miRanda utilized a base scoring system
similar to genome alignment scoring: perfect matches scored highly, G:U wobbles were
permitted and scored moderately, and alignment gaps are strongly penalized. RNA22 identified
sites using pattern recognition, without directly implementing species conservation as a filter.
MirTarget, which hosts its results in miRDB, performs feature selection using support vector
machine (SVM), a form of supervised learning that maximizes separation between two groups in
a multidimensional space. The latest version of MirTarget identified 50 relevant features for
miRNA target prediction through recursive feature elimination, and weights for each feature
were calculated by SVM to generate a score.
Across the majority of prediction algorithms, certain key features are identified as crucial
for miRNA-targeted RNAi: seed sequence complementarity, species conservation, Gibbs free
energy of RNA-RNA binding, and target site accessibility (36). Additional features include
supplementary binding sites, as illustrated by TargetScan and MirTarget, and specific features
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affecting site accessibility, such as nucleotide composition of the target site and neighboring
regions, and location of the target site within the 3’UTR (35,37). Despite algorithmic differences,
the identification of miRNA targets requires the integration of both wet and dry labs, i.e. the
experimental detection of targets and the computational resources to determine the factors that
influence true miRNA-target interactions. Experimental techniques used to both train and
validate these prediction resources range from low-throughput methods such as luciferase assays
to high-throughput methods that include microarrays and next-generation RNA sequencing after
artificial miRNA dysregulation (38,39). The methods for manipulating miRNA expression can
either increase miRNA levels, such as through miRNA overexpression, or decrease miRNA
levels, which has been performed through miRNA sponges and, more recently, CRISPR-Cas9
gene editing (40,41). More recent techniques for identifying miRNA targets without overt
manipulation of expression levels include CLIP-ligation and sequencing, in which the miRNA
and target strands are cross-linked to the Argonaute protein, ligated to create a hybrid, and
sequenced after Argonaute-immunoprecipitation (42,43).

1.2.3. MicroRNAs as Biomarkers for Disease
Expression changes in miRNAs have been associated with developmental growth in
numerous organisms, such as nematodes, fruit flies, and zebrafish, in addition to mammals,
including humans and mice (18,44-46). This suggests that miRNAs can be temporally expressed
specifically to regulate certain cellular and physiological functions. Subsequent changes in
miRNA expression have also been associated with cellular differentiation into various tissue
types (47). By the same token, dysregulation of miRNAs may result in atypical phenotypes and
presentation of various diseases, such as Alzheimer’s disease and cancer (48,49). Although
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miRNA expression changes may not necessarily be the driving factors behind disease
phenotypes, their roles as post-transcriptional regulators cannot be discounted in the propagation
of disease.
The roles of miRNA in cancer development and progression have been extensively
reviewed in the literature, with various focuses such as: the roles of miRNAs on general cellular
dysregulation leading to tumor formation (50-53); diagnostic applications of miRNAs such as in
tumor classification and patient prognosis (54-58); and their potential as therapeutic targets
(54,56,58,59). In the context of tumor development, miRNAs can be expressed and dysregulated
in a manner similar to known oncogenes or tumor suppressors. As a result, miRNAs that are
overexpressed in tumor tissue compared to normal tissue have been described as “oncomiRs.”
Considering the inhibitive regulatory mechanisms in which miRNAs are involved, oncomiRs
typically target tumor suppressor genes, while tumor suppressive miRNAs target oncogenes.
This sort of relationship has been observed with the better known cancer-related miRNAs. For
example the classic oncomiR miR-21-5p, which has been reported as upregulated in
glioblastoma, acute myeloid leukemia, breast cancer, and prostate cancer, among others, is
known to target the tumor suppressor PTEN, PCDC4, TPM1 and TIMP3 (50). Comparatively,
miR-34 acts as a tumor suppressor, targeting the cell cycle activators CDK4, CDK6, cyclin E2,
EZF3, and met (50). It should be recognized, however, that the role of the miRNA as an
oncomiR or a tumor suppressor can be tissue-dependent. miR-221 and miR-222 both are
confirmed to be upregulated and target the oncogene KIT in erythroblastic leukemia, thereby
functioning as tumor suppressor. However, in other tumor types, confirmed targets of miR-221
and miR-222 include the tumor suppressors p27, p57, PTEN and TIMP3, and upregulation of the
miRNAs resulted in inhibition of expression (58). Additionally, the relevant categorization of the
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miRNA as an oncomiR or tumor suppressor is dependent on its directional dysregulation in
tumor tissue.
The expression levels of miRNAs can also be evaluated in a diagnostic context without
requiring an in-depth understanding of potential targets and resulting cellular response. In this
capacity, miRNAs can serve as biomarkers, providing insight into patient risk for developing
cancer, or further risk of cancer death. A number of studies have identified single miRNAs as
potential biomarkers for cancer prognosis. For example, increased miR-126 expression has been
correlated to metastasis in renal clear cell carcinoma while upregulation of miR-31 in cervical
and oropharyngeal cancers is negatively associated with patient survival (41,60,61). Some
groups have also proposed using a panel of miRNAs as a diagnostic indicator, i.e. using the
cumulative expression profile in the form of a prognostic signature. Such signatures have been
derived for a variety of cancers, including cervical cancer (62,63), oropharyngeal cancer (64-66),
and bladder cancer (67). The primary advantage of using multiple miRNAs in a clinical
diagnostic panel is the ability to compensate for technical and biological variability both in
screening techniques and patient cohorts. Even so, not all signatures can be validated despite the
use of rigorous and comprehensive bioinformatics pipelines on large-scale patient cohorts.
The implementation of miRNAs as potential therapeutic targets is a relatively new field
and can be considered a branch of gene therapy in the sense that therapeutic goals are the
inhibition of undesirable miRNA transcripts or enhancement and restoration of pro-survival
miRNAs (68). Inhibition of miRNAs has been performed in vitro through antagomiRs, locked
nucleic acid constructs (LNAs), anti-sense nucleotides and sponges (69). Among animal models
for in vivo miRNA inhibition, experiments have tested: the delivery of miR-10b antagomiRs to
prevent metastasis in tumor bearing mice (70); LNA inhibition of miR-122 to improve hepatitis
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C outlook in primates (71); and miRNA target saturation with sponges (72). Similarly, tumor
suppressive and pro-survival miRNAs have been explored in the context of therapies that restore
their functions. Mouse models have shown that delivery of let-7 miRNAs through lentiviral
constructs and intravenous lipid emulsions were able to reduce tumor burden in mice (73,74),
and restoration of the KRAS targeting miRNAs miR-143 and miR-145a with a nanovector
delivery resulted in the reduction of xenografted pancreatic tumors (75). Recent research has
shown that miRNAs can be inhibited in vivo through CRISPR constructs (41); given the latest
research showing the CRISPR can be used to edit human embryos, there may be future
applications of CRISPR to either inhibit or restore miRNA expression at the genomic level (76).
Despite their distinctively short sequence length, microRNAs function in a significant
role in general cellular biology. As the crucial targeting member of the regulatory RISC body,
miRNAs aid in controlling temporal cell growth and development, as well as later roles in
maintenance of protein expression. Dysregulation of such a diverse controller can lead to disease
formation, which has driven research to determine targets of miRNAs, mechanisms by which
miRNA expression changes occur, and methods to adjust for these changes. Simultaneously, the
relative expression of miRNAs can be explored within the clinical setting to aid diagnosticians in
determining course of treatment, without requiring intervention in the miRNome. As a whole, the
miRNome is a crucial aspect of the human transcriptome, and should not be overlooked in how it
may be explored in the contexts of both general physiology and the course of disease.

1.3

The Role of Human Papillomavirus in Tumor Formation

1.3.1 A Brief History of Oncoviruses
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Viruses are a class of infectious agents that rely on host cells for life cycle progression
and replication. The official classification of viruses is the responsibility of the International
Committee of the Taxonomy of Viruses (ICTV), which assigns viruses to one of eight orders or
otherwise defines a virus order as “unclassified,” based on biological properties such as
pathogenicity and epidemiology, and sequence relationships such as divergence phylogeny
(77,78) (Table 1.3.1). Other classification systems include that proposed by David Baltimore in
1971, which classifies viruses based on nucleic acid (i.e. RNA or DNA), strandedness (single or
double), transcription direction (sense or antisense), and method of replication (e.g. reverse
transcription) (79,80). As of 2017, the eight major ICTV orders can be classified into three
different Baltimore groups, which, in conjunction with the high number of unclassified viral
families, suggests that further classification is ongoing (Table 1.2).
Viral replication can be described as either lytic or nonlytic. Lytic viral infection typically
follows a five step process of adsorption, penetration, replication, assembly, and release (81).
Adsorption and penetration describe the process by which the virus infects the host cell, and viral
mRNAs are produced in the replication phase, either through viral enzymes or host transcription

Table 1.1. ICTV classification of viruses into major orders

Bunyavirales

Number of
families
9

Number of
species
157

[f] Hantaviridae

Caudovirales

3

956

[g] T4virus

Herpesvirales

3

103

[s] Human gammaherpesvirus 4 (Epstein-Barr virus)

Ligamenvirales

2

11

[g] Rudivirus

Mononegavirales

9

212

[g] Ebolavirus

Nidovirales

4

64

[s] SARS coronavirus

Picornavirales

6

196

[s] Foot-and-mouth disease virus

Tymovirales

4

180

[g] Trichovirus

Unassigned

85

2525

[f] Papillomaviridae

Total

125

4404

Order

Example family [f], genus [g], or species [s]
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Table 1.2. Baltimore classification of viruses
Group

Name

Abbreviation

Known orders

Example viruses

I

Double-stranded DNA viruses

dsDNA viruses

Caudovirales
Herpesvirales
Ligamenvirales

Human papillomavirus,
herpesviruses,
adenoviruses

II

Single-stranded DNA viruses

ssDNA virus

Parvoviruses

III

Double-stranded RNA viruses

dsRNA viruses

Rotavirus

IV

Sense single-stranded RNA
viruses

(+)ssRNA
viruses

Antisense single-stranded
RNA viruses
Single-stranded RNA reversetranscribing viruses

(-)ssRNA
viruses
ssRNA-RT
viruses

Double-stranded DNA reversetranscribing viruses

dsDNA-RT
viruses

V
VI
VII

Nidovirales
Picornavirales
Tymovirales
Bunyavirales
Mononegavirales

Rubella virus
Rabies virus
Human
immunodeficiency virus
Hepatitis B virus

factors; in either case, the host translation machinery is utilized to translate viral mRNA
transcripts. Viral progeny is then assembled from the translated proteins and released in the final
phase, which causes cell lysis (81). Nonlytic viruses include retroviruses, a special class that are
able to integrate their own genomic sequences into the host genome. Transcription by the host
produces the viral progeny, which can be then be released through exocytosis without
necessitating host death and lysis (81).
The degree to which various virus families hijack host cellular components for replication
can also be used in classification. DNA viruses (Baltimore Classes I and II) require the host
transcription machinery to produce viral mRNA transcripts before translation (79). Double
stranded RNA viruses (Class III) contain enough information for both protein synthesis and
replication while single-stranded RNA viruses (Classes IV and V) necessitate host production of
template strands (79). Both RNA and DNA retroviruses (Classes VI and VII, respectively),
integrate into the host genome through transcription, which makes viral clearance by the host
much more difficult (79,80). For these two particular viral classes, integration is crucial to
replication and survival; however, genomic integration of viral sequences has been observed by
14

other classes, such as the Class I human papillomavirus, as a result of chromosomal instability
and recombination of cellular and viral genome fragments (82).
In addition to utilizing the transcription and translation machinery, viruses will also alter
the cellular environment in order to favor viral replication. Examples include: the degradation of
host mRNA via viral endoribonucleases by alphaherpesviruses, so as to reduce competition for
translational machinery (83); viral stimulation of the cell cycle to improve environmental
conditions for replication by polyomaviruses and adenoviruses (84,85); and competition for
translational machinery through internal ribosome entry sites by hepatitis C virus (86).
Additional viral responses may interfere with immune response or apoptotic signaling (87,88).
The alteration of the internal environment to favor the viral life cycle is rarely to the benefit of
the host, and in some organisms, can lead to abnormal cell growth and replication, and
subsequent tumor formation. The subset of viruses that are capable of inducing such transition
has accordingly been termed “oncoviruses.”
The first known oncovirus was described in 1911 by Peyton Rous, who discovered the
Rous sarcoma virus in chickens (89). The first human virus linked to tumorigenesis was the
Epstein-Barr virus (EBV) which was strongly correlated with Burkitt’s lymphoma in the 1960s,
and later to nasopharyngeal carcinoma (90,91). Through the 1970s and 1980s, the list of
oncoviruses grew to include human papillomavirus (HPV) as a potential causative factor in
cervical cancers, hepatitis B virus (HBV) as associated with hepatocellular carcinoma , and
human T-cell leukemia virus type 1 (HTLV-1) (92-96). The existence of hepatitis C virus (HCV)
was initially proposed in 1975, but was not confirmed until almost 15 years later, as well as its
potential role in the development of hepatocellular carcinoma (97-99). More recent technologies
have led to the identification of Kaposi’s sarcoma associated herpesvirus in the 1990s and the
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role of Merkel cell polyomavirus in Merkel cell carcinoma (100,101). To date, these seven
viruses make up the breadth of known human oncoviruses. Additional oncogenic viruses have
been discovered in other species, including Marek’s disease virus in chickens, simian
vacuolating virus 40 (SV40) in some animal models, and feline leukemia virus in chickens (102104).
The primary mechanisms of infection and tumor formation can vary between the seven
human oncoviruses (reviewed in depth by White et al. (11) and Mesri et al. (105)). Epstein-Barr
virus is well-characterized as the causative agent of classical acute infectious mononucleosis;
transmission primarily occurs via saliva, as well as potentially through sexual contact (106). The
hepatitis viruses, despite being of different families, are both transmitted through bodily fluids
via interactions such as sexual intercourse or shared intravenous needles (107,108). HPV
transmission is through mucosal and skin-to-skin contact, the latter of which is further

Table 1.3. Human oncoviruses and associated viral oncoproteins
Virus

Epstein-Barr virus

Family and
Abbreviation Baltimore
classification

Associated cancers

Selected viral
oncoproteins

Herpesviridae
I (dsDNA)

Burkitt’s lymphoma
Nasopharyngeal
carcinoma

EBNA1
LMP1
LMP2A
LMP2B

Herpesviridae
I (dsDNA)

Kaposi’s sarcoma

LANA
LAMP

Hepadnaviridae
VII (dsDNA-RT)
Flaviviridae
IV ((+)ssRNA)
Retroviridae
VI (ssRNA-RT)
Polyomaviridae
I (dsDNA)

Hepatocellular
carcinoma
Hepatocellular
carcinoma

EBV

Kaposi’s sarcomaKSHV
associated herpesvirus
Hepatitis B virus

HBV

Hepatitis C virus

HCV

Human T-cell
leukemia virus type 1
Merkel cell
polyomavirus
Human
papillomavirus

HTLV-1
MCV

HPV

Papillomaviridae
I (dsDNA)

16

HBx
HCV core protein
NS3

Adult T-cell leukemia

Tax

Merkel cell carcinoma

Large T-antigen
Small t-antigen

Cervical cancer
Anal cancer
Penile cancer
Oropharyngeal cancer

E6
E7

compounded by epithelial microabrasions (109). Transmission of HTLV-1 is conducted
primarily through mother-to-child interactions, sexual intercourse, or blood transfusions, the
latter of which has been mostly controlled for by screening donated blood (110). KSHV is
transmitted in children through saliva, and in adults through high-risk sexual activity (111). The
least understood mechanism of oncovirus transmission is that of MCV; current hypotheses
suggest that dermal fibroblasts are infected by MCV and are either transformed into Merkel cells
or infect neighboring cells (112). The viral mechanisms leading to tumorigenesis are much more
clearly understood, and encompass a variety of cellular modifications and responses (Table 1.3).
Both Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus are members of the
Herpesviridae family (Baltimore Group I), which are characterized by their latency states. EBV
expresses the oncoproteins EBV nuclear antigen (EBNA1) and latent membrane proteins 1 and 2
(LMP1 and LMP2A/B). The primary function of EBNA1 is to promote viral proliferation. By
binding to host DNA and regulating host cellular transcription, EBNA1 encourages EBV
episomal retention and segregation, as well as preventing cell death (113). LMP1 and LMP2 are
two latency associated viral proteins that mimic oncogenic proliferative signals. LMP1 imitates
an active CD40 receptor, which recruits TRAFs and causes NF-κB activation, a known factor in
lymphoma formation (114). The LMP2 proteins mimic a cross-linked Ig receptor, which leads to
the activation of the PI3K-Akt-MTor pathways, which in turn promotes B-cell differentiation,
prolonged survival, and cell growth (115,116). Similarly, KSHV expresses the KSHV latency
associated nuclear antigen (LANA), which connects the KSHV episome to the host (117). In
doing so, KSHV also compromises a number of cellular regulators, including p53, pRb, GSK-3β,
and p300 (118). KSHV also expresses latency associated membrane protein (LAMP), which
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resembles LMP1 in function and activates anti-apoptotic pathways, including Ras/MAPK, NFκB, and vIRF3 (119).
The hepatitis viruses HBV and HCV are members of different viral families linked only
by their targeted infection of the liver. HBV is a double-stranded DNA hepadnavirus (Baltimore
Group VII) that encodes the viral oncoprotein HBx, which can stimulate cell cycle entry, as well
as survival pathways such as Ras and NF-κB (120). Regarding apoptosis, HBx can either prevent
apoptosis by blocking caspase activity and directly interacting with p53, or or promot TNGmediated cell death, potentially to increase hepatocyte regeneration (120). HBx is also capable of
activating the pRb-E2F1 oncogenic pathway through p16INK4a inactivation via phosphorylation
(121). In comparison, HCV is a single-stranded sense RNA virus (Baltimore Group IV), and as
such, is not integrated into host genome. The primary viral proteins behind HCV-driven
oncogenesis are currently believed to be the HCV core protein and nonstructured protein 3
(NS3). HCV core protein has been shown to interact with a number of transcription factors and
regulators, including p53, p21, and NF-κB, as well as the Ras/Raf/MAPK pathway, while NS3
has been shown to bind and inactivate p53 (122,123).
HTLV-1 is an RNA retrovirus (Baltimore Group VI) that encodes a variety of
oncoproteins. The Tax protein is particularly effective in activating cell proliferation and survival
through various mechanisms. Tax binds directly to CREB to induce and increase viral
transcription, which is accentuated by the recruitment of p300 (124). Tax is also able to activate
NF-κB to induce celluar transformation, as well advance cell cycle progression by activating
cyclin E and Cdk2, stabilizing cyclins D2 and D3 and the cyclin D/Cdk4 complexes (124).
Through these mechanisms, Tax is able to induce phosphorylation of pRb and E2F release (124).
HTLV-1 also encodes HBZ, which is implied to activate the transcription of the pro-survival
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genes JUND, JUN, and ATF, as well as promoting transcription of E2F to induce cell
proliferation and hTERT expression to confer cell cycle immortality (124,125).
Merkel cell polyomavirus is a polyomavirus (Group I) that was discovered to be
integrated into the genome in most Merkel cell carcinomas. Given the relatively recent discovery
of MCV as a causative agent of MCC, the mechanisms by which MCV integration induces tumor
formation are still under investigation. Another tumorigenic polyomavirus, SV40, has provided
some guidance, particularly with a focus on large T- and small t-antigen functions (126). Coimmunoprecipitation experiments have shown that large T-antigen is bound to pRb, thereby
inducing cell cycle progression, as well as disrupting lysosomal clustering by binding to Vam6p
(127). The MCV small t-antigen also binds to and hyperphosphorylates the transcription
initiation factor 4E-BP1 to dysregulate cap-dependent translation, and binds to the E3 ubiquitin
ligase Fbw7, resulting in increased c-myc and cylin E activity (128,129).

1.3.2 Functions of Human Papillomavirus Proteins
Papillomaviruses (PVs) are a family of double-stranded DNA viruses with genomes that
are approximately 8 kilobases long, encased in an icosahedral capsid (Figure 1.2) (130,131).
Taxonomically, the Papillomaviridae family consists of 48 genera (with one “unclassified”
genus), encompassing 123 clearly defined species, with an additional 18 species presently
defined as “unclassified” (132). The PV species are divided into types, which can be further
classified into subtypes and variants (130), 183 of which are human specific (i.e. human
papillomavirus (HPVs)) and are members of the genera alphapapillomavirus,
betapapillomavirus, gammapapillomavirus, mupapillomavirus, and nupapillomavirus. High-risk
HPV types, specifically those associated with oncogenesis, are typically in the alpha-
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papillomavirus genus. HPV infects the basal layer of mucosal and epithelial cells, normally
through microlesions and microabrasions (133). The most common visible symptoms of HPV

A

B

Figure 1.2. Structure of the HPV viroid and genome. (A) L1 protein monomers selfassemble into pentamers and L2 monomers reside in the center of the pentamers. 72
capsomers form the icosahedral HPV virion. Adapted from Schiller and Muller (209). (B)
The HPV16 genome, as a representative HPV type, is circular and encodes for eight
proteins: E1, E2, E4, E5, E6, E7, L1, and L2. Adapted from the Papillomavirus Episteme
(pave.niaid.nih.gov) (128).
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are benign tumors, namely warts and papillomas. However, symptoms are often invisible to the
naked eye, taking the form of microlesions. Overt lesions often are the result of immune
suppression; otherwise, the majority of HPV types coexist silently with the host (133).
A typical papillomavirus encodes 7 proteins: the early proteins E1, E2, E4, E6, and E7,
and the late proteins L1 and L2; some PV types, including those that infect humans, encode an
additional early protein, E5 (134). The HPV replication cycle progresses through a number of
well-characterized steps, which can be expounded on in the context of viral protein expression
and function (reviewed concisely by Graham (134)). After infection of basal cells and successful
translocation to the nucleus, the first viral genes to be expressed are E1 and E2. Functionally, E1
and E2 work in conjunction to bind to the viral origin of replication. E2 acts as a tether and
recruits E1 to the binding site, and E1 recruits cellular transcription and replication factors for
viral genome amplification (135,136). E2 also maintains viral genome levels by tethering the
viral genome to host chromatin binding proteins, as well as temporally limiting viral
transcription to prevent immune activation (136). E6 and E7 are transcribed initially during the
early stages of the replication cycle, but transcript and protein expression levels are not likely to
be depleted until the virus is cleared (134). Despite their primary recognition as the HPV
oncogenes, their roles are vital for viral replication. E6 and E7 function in tandem to promote
cell proliferation, and subsequently viral proliferation, without inducing apoptosis (137,138). The
mechanisms by which this is performed can lead to oncogenesis when left unchecked. The E4
and E5 proteins are not as well studied as the other HPV proteins, but their general functions
have been elucidated. E4 is encoded within E2; it contributes to genome amplification and capsid
synthesis, and may arrest cell-cycle in G2 phase (139). E4 has also been noted for its abundant
expression in upper epithelial layers, and consequently been proposed as a biomarker for HPV
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infection (139). E5 is not expressed by all papillomaviruses, but in those that do, it is shown to
have a variety of possible functions (140). It is weakly oncogenic, possibly supplementing E6
and E7 activity as a cofactor by upregulating EGFR signaling pathways, as well as possibly

A
E6
E6AP
p53

p53 Degradation

Ubiquitin

B
E7

E7
pRB

pRB

E2F1

E2F1

Figure 1.3. Oncogenic activity of the HPV E6 and E7 proteins. (A) The E6 protein induces
tumor formation by binding to the E6 associated protein (E6AP) and the tumor suppressor
p53. E6AP then recruits ubiquitins to target p53 for degradation. (B) The E7 protein
functions by binding to the tumor suppressor pRB, which releases the transcription factor
E2F1. E2F1 is then free to transcribe genes associated with cell cycle progression. Adapted
from Yim and Park (140).
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impairing intercellular communication by binding with vacuolar ATPase. This latter property,
along with inhibition of HLA-1 intracellular transport, may contribute to immune evasion (140).
The late proteins are the structural capsid proteins for HPV. The major capsid protein L1
is a protein of approximately 55 kilodaltons that can spontaneously self-assemble into virus-like
particles (131). The L1 proteins form a pentameric capsomer; 72 capsomers self-assemble into
the icosahedral virion (131). Each capsomer binds to an L2 minor capsid protein, in such a
manner that the mature virion keeps most the L2 protein body concealed below the capsid
surface (131,141). When the virus encounters the host cell surface, L1 interacts with heparin
sulfate carbohydrates on basement membrane proteoglycans (131). This induces a
conformational change in L1 that exposed L2. L2 cleavage by furin allows for a conformational
change that in turn binds to a secondary receptor on the cellular plasma membrane (141).
Subsequent cell entry resembles micropinocytosis, after which the virion is transported to the
nucleus through membrane bound cellular components and tubulin transport (134). Nuclear entry
can occur either through nuclear pores or in the midst of nuclear envelope dissolution during
mitosis (134).
As mentioned previously, E6 and E7 contribute to the viral life cycle but are also the
primary drivers of HPV-induced oncogenesis and have been extensively reviewed in the
literature (Figure 1.3) (142-145). The classical mechanism by which E6 induces oncogenesis is
also arguably the best described function of the protein. E6 targets and binds proteins with an
LXXL motif (137). Included among these is the E6 associated protein (E6AP), an ubiquitin
ligase encoded by the UBE3A gene. This interaction results in a conformational change in E6
that allows it to recruit the regulatory protein p53, forming a ternary complex. In doing so,
ubiquitin peptides are transported from E6AP to p53, turning p53 into a target for degradation
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(146). As a tumor suppressor, p53 is involved in promoting cell cycle arrest and apoptosis in the
event of cellular stress; subsequently, p53 degradation can result in cell immortality and
eventually tumor formation (147). E6 is also capable of targeting other cellular regulatory
proteins, including p300/CBP, HIF-1α/HIF-2α, and MAML1 (148). It should be noted that these
latter interactions are more often observed in lower-risk HPV types, and certain HPV types also
exhibit preferential binding; experiments where E6 binding partners are coexpressed
demonstrated that high-risk E6 proteins bind to E6AP more often than other candidates, and the
low-risk HPV E6 prefers alternate candidates (148,149).
Another observed E6 interaction is the activation of the telomerase enzyme hTERT,
which adds telomere repeats to the ends of chromosomes, and essentially conferring immortality
(150). This particular response is notable for its independence from E6-p53 activity, but it does
appear to require E6AP, at least in high-risk HPV types (151,152). E6 alterations of cellular
transcription levels are mediated by its interaction with histone acetyltransferases, including
degradation of Ada3 and Tip60, along with p300 (137). Further compromising cellular
homeostasis are E6 effects on PDK1 and mTORC2, which lead to the activation of Akt and the
mTORC1 signaling pathway, resulting in increased metabolism (153,154). E6 is also known to
affect immune response by activating NF-κB, increase proliferation and prevent apoptosis by
binding to and degrading Bak, and inhibit additional apoptotic signaling cascades by binding to
procaspase 8 (155-157). The interferon signaling cascade is also inhibited by E6 binding Tyk2, a
member of the Jak/Stat signaling pathway, and IRF3, thereby preventing activation of interferon
responsive genes (158,159).
The primary oncogenic mechanism of E7 is through its interaction with the pRB
pathway, by binding directly to the retinoblastoma protein (pRB) at an LXCXE domain, leading
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to its phosphorylation and degradation (160,161). Reduced pRB level leads to the release of E2F,
a transcription factor that controls for proliferative genes. An additional function of E2F is the
activation of p53, which under normal circumstances would increase the likelihood of cell death;
however, this is mitigated by E6-mediated p53 degradation (142). E7 has been proposed as the
primary oncogenic mechanism of HPV, as transfection of the E7 gene initiated benign tumor
growth, while E6 induced the conversion from benignity to malignancy (162). Recent research
has also found that E7 conservation was crucial to tumor formation, supporting the hypothesis of
E7 as the primary oncogenic factor; a significantly lower frequency of variants was identified in
patients whose HPV infection progressed to cervical cancer (163). Supplementary E7 functions
leading to tumor formation include binding and inhibiting cyclin-dependent kinase inhibitors,
including p21Cip1 and p27Kip1 (164,165).

1.3.3 Human Papillomavirus and Other Oncoviruses Can Alter MicroRNA
Expression
Oncoviruses are not restricted to direct interaction with cellular regulatory proteins in
tumorigenesis; further indirect mechanisms, such as RISC, can be affected as well. The first
discovery of viral encoded miRNAs was reported in B-cells infected with EBV (166). In the
years since, over 500 miRNAs have been identified as virally encoded and curated in miRBase
(22). The majority of functional viral miRNAs have been identified in members of the
herpesvirus family, some of which have been previously described as oncoviruses; other
potential viral miRNAs have been identified in polyomaviruses and adenoviruses (reviewed by
Roberts, Lewis, and Jopling (167), and Skalsky and Cullen (168)).
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Five major species of herpesvirus have been identified as coding functional miRNAs. Of
note are the gammaherpesviruses, EBV and KSHV. Since the first discovery of viral miRNAs in
EBV, 25 total pre-miRNAs have been reported (169,170). Notable miRNAs in EBV are miRBART2, miR-BART5, and miR-BHRF1-3. miR-BART5 targets the cellular proapoptotic protein
PUMA while miR-BHRF1-3 targets the cellular T-cell attractant CXCL11 (171,172). miRBART2 has been shown to target MICB, thereby improving immune evasion (173). Viral targets
of EBV miRNAs include the lytic gene BALF5 by miR-BART2, presumably to stabilize viral
latency, and LMP1 by three other EBV miRNAs (174,175). KSHV expresses a total of 12 premiRNAs (168). Viral-viral interactions include the targeting of RTA by miR-K12-9-5p, which
prevents early entry into the lytic cycle (176). Host cellular target interactions with KSHV
miRNAs include: MICB by miR-K12-7; the apoptotic protein BCLAF1 by miR-K12-5, -9 and 10; the T-cell attractant THBS1 by miR-K12-1, -3-3p, -6-3p, and -11; p21 by miR-K12-1; the
transcriptional repressor MAF by miR-K12-6 and -11; and the transcriptional repressor BACH1
by miR-K12-11 (173,177-181).
As previously indicated, SV40 is a polyomavirus that has also been shown to be
potentially oncogenic; it also encodes a single pre-miRNA that targets the viral large T-antigen,
which improves immune invasion (182). Both the miRNA and target are conserved in other
polyomaviruses, including MCV, human BK virus, and JC virus (183,184). Some adenoviruses
have also been shown to produce non-coding RNAs, VAI and VAII, that interact with DICER
and the miRNA RISC complex (185,186). The only known direct target is the proapoptotic RNA
metabolism factor TIA-1, but no significant effects were observed (187).
Alterations in miRNA activity in response to viral infection is not limited to virally
encoded miRNAs, as the host miRNome also undergoes dysregulation. The interactions can be
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essentially be classified into one of two categories: viral regulation of cellular miRNAs, and host
regulation of viruses through miRNA-RISC. It should be noted, though, that sometimes both
interactions are observed simultaneously.
Virally induced dysregulation of miRNA expression typically results in a response
favorable to viral survival, such as increased immune evasion or improved environment for
replication. Among the known oncoviruses, EBV upregulates miR-155 and miR-146a
expression, both of which have been shown to target TRAF and IRAK1, which results in
inhibited immune response (188-190). EBV also upregulates miR-29b, which targets TCL1,
affecting cell survival, and miR-21, which is upregulated in several cancer types (175,191).
KSHV, as previously described, encodes miR-K12-11, which is a functional mimic of miR-155;
both the host and the viral mimic miRNAs target transcription factors, and subsequently
contribute to oncogenesis (181). This latter viral miRNA is also observed in other herpesviruses
shown to cause cancer in other organisms, such as Marek’s disease virus in chickens (192).
HCMV downregulates miR-100 and miR-101, which have been shown to inhibit HCMV
replication (193). Among non-herpesvirus miRNA effectors, HIV-1 was shown to promote
replication by downregulating members of the miR-17/92 cluster (194).
Host miRNAs are also capable of targeting viral genes, although the infection agent may
take advantage of the host response. This is observed in HCMV and HSV-1, as miR-200 targets
the HCMV protein IE2 and miR-138 targets the HSV-1 protein ICP0; downregulation of these
two proteins help promote viral latency and survival (195,196). Not all miRNA responses are to
the detriment of the host, as miR-29a is upregulated in response to HIV infection, and
specifically targets the HIV-1 transcript for degradation (197). Hepatitis C virus was also shown
to indirectly induce the overexpression of a number of miRNAs, including miR-196, miR-296,
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and miR-351 through increased IFN-β activity, but these miRNAs appear to modulate HCV
replication (198).
HPV has been shown to dysregulate a number of miRNAs, notably downregulating miR143, miR-145, miR-34a, and miR-203, resulting in increased cell motility (199-202). miR-145
downregulation also results in genome amplification associated with cellular replication and
growth (203). The downregulation of miR-218 by HPV results in increased translation of its
target LAMB3, a protein specific to epithelial cells that may play a role in differentiation and
oncogenesis (204). Upregulated miRNAs include miR-9, which has been shown to be
upregulated in HPV(+) cervical cancers by the E6 protein, especially by HPV16 (205). HPV16
E6 also specifically represses miR-23b in cervical cancer, which is an apoptotic tumor
suppressor that regulates the anti-apoptotic oncogene c-MET (206). Additional HPV-associated
miRNAs in cervical cancer include the upregulated miR-16, miR-25, miR-92a, and miR-378,
and the downregulated miR-22, miR-27a, mir-29a, and miR-100 (207). Within oropharyngeal
cancers, HPV infection is associated with upregulation of miR-9, similar to the observation in
cervical cancer, and miR-155, along with downregulation of miR-31, miR-223,and miR-18a
(64). A few analyses have looked at the role of HPV in miRNA expression changes for both
oropharyngeal and cervical cancers, and have concluded that some similarities exist between the
two cancer types, particularly upregulation of miR-10b, miR-16, and miR-20b, along with
downregulation of miR-145, miR-199a and miR-199b (208). Direct expression of E6 and
E7proteins from HPV16 in non-tumor tissues yielded similar results, as well as demonstrating
how characteristic oncomiRs and tumor suppressive miRs such as miR-203a can influence the
transcriptome (209).
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1.4

Characterization of Cervical and Oropharyngeal Cancer in the

Context of HPV
In the context of cervical cancer, Harald zur Hausen proposed a link between tumor
formation and HPV infection status in 1974; this research garnered him the Nobel Prize in
medicine in 2008 (92,93). Cervical cancer is the most common gynecological tumor in the
world, with approximately 528,000 new cases diagnosed annually (210). Of these cases, it is
estimated that 95% are the result of HPV infection (211). This direct causation has spurred
research into HPV vaccines with the intent of reducing overall risk of cervical and other
anogenital cancers, leading to the first marketed vaccines: Gardasil, from Merck, inoculated
against HPV types 6, 11, 16, and 18; and Cervarix from GlaxoSmithKline, protected against
types 16 and 18 (212,213). HPV types 16 and 18 alone are estimated to be responsible for 70%
of new cervical cancers. The next generation of Gardasil also protects against the high-risk HPV
types 31, 33, 45, 52, and 58, thereby increasing the coverage to viral types responsible for up to
90% of potential cervical cancers (214).

1.4.1 Tumor Source Site and Genomics Affect Cervical Cancer Prognosis
Despite its oncogenic properties, HPV infection has also been shown to be a positive
prognostic marker for overall patient tumor outcome (215-218). The mechanisms behind this
duality are not entirely understood, which has encouraged deeper research into the genomic
alterations that result from and occur independently of HPV infection. Some of these differences
can be attributed to variance in tissue source site, as cervical cancer can be categorized primarily
into cervical squamous cell carcinomas (which constitute approximately 75-80% of cervical
cancer diagnoses), adenosquamous cell carcinomas, and adenocarcinomas (219-221). EGFR
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mutations have been reported as more frequent in squamous cell carcinomas, while
adenocarcinomas demonstrated a significantly higher rate of KRAS mutations; both cervical
cancer types also demonstrated a notable rate of PIK3CA mutations that were a marker for
poorer patient prognosis (222). Interestingly, it has also been reported that adenocarcinomas and
adenosquamous cell carcinomas are infected by alphapapillomavirus 7 types, specifically HPV
18, more frequently than squamous cell carcinomas; it should be noted that HPV16 is still the
most prevalent infectious HPV type in cervical cancer independent of tumor source site (223).
Additionally, infection by alphapapillomavirus 7 types has been indicated as a greater risk factor
for survival than alphapapillomavirus 9 types (224-227). This variance may account for some of
the reports that patients with squamous cell carcinomas generally have better outcomes than
patients with adenosquamous cell and adenocarcinoma, although some literature also propose
that there is no difference in patient outcome based on tumor source site (228-233).
Nonetheless, research has consistently shown that HPV(-) tumors have worse outcome
than tumors with any sort of HPV infection (227,234). This may be attributable to some of the
genomic alterations that have been identified. This includes PIK3CA, KRAS, and EGFR, as
previously described (222). Additional large-scale genomic studies have also been performed to
confirm previously described genomic alterations, as well as identify novel features. One study
published in 2014 analyzing samples from 115 cervical cancer patients confirmed literature
reports of PTEN and STK11 in squamous cell carcinomas, as well as describing novel mutations
in EP300, FBXW7, HLA-B, MAPK1, and NFE2L2 (235). Many of these mutations have been
identified in other cancer types. Specifically, FBX27 and EP300 have been identified as mutated
in endometrial and head and neck cancers, HLA-B mutants correspond with HLA-A and B2M
mutants in lung squamous cell carcinomas. The specific MAPK1 mutations identified in this
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study was also found in an oropharyngeal cancer cell line, and the NFE2L2 mutation was
previously described in lung squamous cancers. Another notable large-scale genomic study was
published recently by The Cancer Genome Atlas Research Network that included 178 patient
samples (236). This study confirmed the aforementioned mutants as occurring with significant
frequency, as well as identifying the novel mutants SHKBP1, ERBB3, CASP8, HLA-A and
TGFRB2; notably, mutations in HLA-A, HLA-B, NFE2L2, MAPK1, CASP8, SHKB1 and
TGFRB2 were exclusive to squamous cell carcinomas. This study also examined copy number
alterations and transcriptome levels for both coding and noncoding RNAs to identify three major
clusters of cervical cancers: high-keratin squamous cell tumors, low-keratin squamous cell
tumors, and adenocarcinomas. Alphapapillomavirus 7 types were confirmed to be enriched in the
adenocarcinoma and low-keratin clusters. Meanwhile, HPV(-) tumors demonstrated higher rates
of KRAS, ARID1, and PTEN mutations, which may indicate possible rationales for higher
treatment failure rates (236).

1.4.2 HPV Distinguishes Oropharyngeal Cancers from Other Head and Neck
Tumors
This pattern of HPV status positively affecting cancer prognosis extends beyond
anogenital tumors. Oropharyngeal tumors are cancers of the oropharynx, a region that includes
the base of the tongue, the tonsils, soft palate, and walls of the pharynx. Traditional causes of
OPSCC include tobacco and alcohol consumption, but there has been an increase of HPV(+)
oropharyngeal cancer diagnoses despite the overall decrease in total new OPSCC cases (237).
HPV(+) cases now approximate 75% of new oropharyngeal cancer diagnoses; this rise has been
attributed to an increase in frequency of oral sexual behaviors (238,239). The mechanism for
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HPV-induced oncogenesis is unchanged; however, due to differences in tissue type, the genomic
characterization of additional oncogenic behavior differs somewhat from what has been observed
in cervical cancers.
Similarly to cervical cancers, large-scale genomic studies have been performed to analyze
the host genome alterations associated with oropharyngeal tumor formation and progression.
Two of the larger studies in the literature analyzed head and neck squamous cell carcinomas as a
whole. The first study by Parfenov and colleagues analyzed the immediate effects of HPV
infection in head and neck tumors (240). Of the 279 tumor samples retrieved, 35 were identified
as HPV(+); 29 were HPV16(+), while the remainder were positive for HPV33 or HPV35, and of
the 35, 25 showed genomic integration. Genomic integration tended to be near coding regions
and may be associated with somatic mutations of genes near the integration sites, including the
silencing mutations of the DNA repair protein RAD51B, the tumor suppressor ETS2, and the
apoptotic gene PDL1, as well as amplification of the oncogene NR4A2 (240).
Utilizing the same cohort, The Cancer Genome Atlas Research Network identified 36
HPV(+) tumors (241). Additionally, 33 samples were identified as oropharyngeal cancers, 21 of
which were in the HPV(+) cohort, indicating an enrichment of HPV(+) tumors in the
oropharynx as compared to other tumor source sites in the head and neck. Throughout the
HPV(+) cohort, there was a significant number of deletions and truncations of TRAF3, as well as
amplification of E2F1. Comparatively, HPV(-) HNSCCs were noted for having deletions in
NSD1, as well as tumor suppressors such as NOTCH1 and CDKN2A. In addition to this, HPV(-)
tumors in the head and neck showed amplification of receptor tyrosine kinases such as EGFR
and ERBB2, which promote cell proliferation, as well as activating mutations of the oncogene
HRAS and inactivating mutations of the proapoptotic factor CASP8. Independently of HPV
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status, TCGA identified amplifications of a chromosomal region containing the transcription
factors TP63and SOX2, as well as the oncogene PIK3CA. HPV(-) tumors also contained
inactivating mutations of CDKN2A, TP 53, and FAT1 at a higher rate than HPV(+) tumors;
comparatively, HPV(+) tumors were contained activating mutations of PIK3CA in addition to
the HPV-independent regional amplification (241).

1.4.3 Applications of Human Papillomavirus in the Diagnostic Setting
Beyond the obvious implications of HPV presenting as a possible factor for oncogenesis,
HPV status is also being used as a diagnostic criterion in the clinic. A pair of studies including
111 patients in Canada and 323 patients in the United States both confirmed the utility of HPV
status as an independent prognostic factor in head and neck cancers (216,217). As a treatment
target, HPV vaccines have been described as a preventative measure. Additionally, some
treatments have been designed to target HPV(-) tumors more specifically, such as the use of the
hybrid human/mouse mAb cetuximab (trade name Erbitux) or the pure human mAb
panitumumab (Vectibix) to target and inhibit EGFR, in addition to the current standard of
cisplatin and radiotherapy (242-244). On the opposite end of the treatment spectrum, HPV(+)
oropharyngeal cancer patients may qualify for de-escalation protocols, some which have been
reviewed by Masterson and colleagues (245). In their review and meta-study, it was concluded
that reduction in radiation intensity for lower-risk, i.e. HPV(+), patients merited continued
investigation. Regarding the change in treatment modalities to replace cisplatin with EGFR
inhibitors, reports were mixed, with one study suggesting that the treatment was more effective
in the HPV(-) cohort, thereby increasing the risk for HPV(+) patients unnecessarily. Despite this,
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authors still recommended continued investigation, as metastasis-free survival after EGFR-mAb
treatment was not yet clearly defined.
In the years since HPV was hypothesized to be an oncovirus, and later confirmed to be a
the primary cause of cervical cancer, there has been a concentrated study of how an external
factor such as a virus can alter the cellular environment so drastically as to induce tumor
formation. Simultaneously, clinical studies have focused on prevention and treatment, leading to
the creation of the HPV vaccine, with the long-term goal of eliminating virally-induced cervical
cancer. Until the time that universal vaccination eradicates HPV as a sexually-transmitted
infection, there remains a need for biological studies to elucidate mechanisms of HPV-based
tumor formation and survival. Such research is translatable to the clinical setting, where
treatments can be designed to target and interfere with HPV-controlled functions, as well as
determine appropriate courses of treatment in accordance with modern paradigm of personalized
medicine. As such, further diagnostic parameters that can stratify patients based on risk of
treatment failure, both independently and in concordance with HPV status, will continue to be in
demand and relevant until widespread vaccination and prevention is attained.

1.5

Project Aims

The goals of this project were threefold:
1. To develop a bioinformatics pipeline to identify biomarkers in HPV-related cancers
available in TCGA, and design prognostic signatures for HPV-related cancers based on
RNA sequencing and miRNA sequencing data;
2. To apply this bioinformatics pipeline to the cancer data from TCGA as a whole and
identify potential biomarkers across multiple cancer types;
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3. To obtain insight into how these biomarkers function within HPV-related cancers and the
mechanisms effected in increasing or decreasing patient risk.
In order to conduct this first aim, we developed a comprehensive approach to identify HPV
status of tumor samples in oropharyngeal and cervical cancer patients using RNA-Seq data, as
well as determine the expression level of coding transcripts. A parallel pipeline was also
designed to identify dysregulated miRNA transcripts from miRNA-Seq data. By combining the
results of these transcriptomic datasets with clinical data provided by TCGA, we were able to
determine the contribution of miRNA and RNA expression levels to overall patient survival. A
rigorous process was then used to select a subset of these biomarkers in the design of prognostic
survival signatures. Within oropharyngeal cancer, we were able to not only design an HPVindependent prognostic signature based on the expression level of four microRNAs, but also
experimentally validate the signature in an independent dataset using quantitative reverse
transcription polymerase chain reaction, thereby demonstrating that the signature can potentially
be applied and evaluated within a clinical setting in a cost-effective manner.
The purpose of the second aim is to show that these bioinformatics pipelines can be extended
beyond the scope of HPV-dependent cancers. By developing statistical programs to perform
automated analysis, we were able to identify miRNAs in the TCGA dataset that were related to
cancer development, progression, and cancer survival in a type specific manner. Additionally, we
extended the miRNA analysis to incorporate target prediction, so as to identify potential genes
that may be controlled by dysregulated miRNAs both within and between cancer types. The
results of this analysis have been made publicly available at oncomir.org, a combined database
and web server for cancer-related miRNAs. The server is also capable of performing de novo
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analysis for miRNA-based survival signatures and the identification of miRNA-based clusters of
cancer types.
The third aim of this project is to expand on the known biology of HPV-induced
carcinogenesis and tumor survival. The mechanisms by which high-risk HPV types lead to tumor
formation through the E6 and E7 proteins are extremely well-documented, and more recent
studies have begun to examine the rationale behind HPV being a positive biomarker for diseasefree and overall patient survival. Intermediate regulatory networks, such as those mediated by
miRNAs, are less well-studied, but may provide a greater insight into properties of HPV-related
tumor survival. By conducting a pathway analysis based on miRNA response to HPV that
focuses on the miRNA-target regulatory interactions, we demonstrate which pathways
supplement the traditional E6/E7 mechanisms in tumor formation, as well as the mutation-driven
pathways in HPV(-) tumors that portend less favorable patient outcomes. This also provides
guidance for future research, as the pathways identified may be candidates for pharmaceutical
therapies in HPV-defined patient populations.
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Chapter 2: Prognostic miRNA Signatures
Derived from The Cancer Genome Atlas for
Cancers of the Head and Neck and the
Cervix
This chapter is adapted from and expanded upon the following publication (1):
Wong, Nathan, Shariq S Khwaja, Callie M Baker, Hiram A Gay, Wade L Thorstad, Mackenzie
D Daly, James S Lewis, Xiaowei Wang. (2016) Prognostic microRNA signatures derived from
The Cancer Genome Atlas for head and neck squamous cell carcinomas. Cancer Medicine 5(7):
1619-1628.

2.1

Abstract

BACKGROUND: Identification of novel prognostic biomarkers typically requires a large
dataset which provides sufficient statistical power for discovery research. To this end, we took
advantage of the high-throughput data from The Cancer Genome Atlas (TCGA) to identify a set
of prognostic biomarkers in head and neck squamous cell carcinomas (HNSCC) including
oropharyngeal squamous cell carcinoma (OPSCC) and other subtypes, and cervical squamous
cell carcinomas (CESC).
METHODS: In this study we analyzed miRNA-seq data obtained from TCGA patients to
identify prognostic biomarkers for OPSCC. The identified miRNAs were further tested with an
independent cohort. miRNA-seq data from TCGA was also analyzed to identify prognostic
miRNAs in oral cavity squamous cell carcinoma (OSCC), laryngeal squamous cell carcinoma
(LSCC), and cervical squamous cell and endocervical carcinoma (CESC).
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RESULTS: Our study identified that miR-193b-3p and miR-455-5p were positively associated
with survival, and miR-92a-3p and miR-497-5p were negatively associated with survival in
OPSCC. A combined expression signature of these four miRNAs was prognostic of overall
survival in OPSCC, and more importantly, this signature was validated in an independent
OPSCC cohort. Furthermore, we identified four miRNAs each in oral squamous cell carcinoma
(OSCC) and laryngeal squamous cell carcinoma (LSCC) that were prognostic of survival, and
combined signatures were specific for subtypes of HNSCC. An additional signature was
developed for CESC that was significant across cervical tumor subtypes.
CONCLUSIONS: A robust 4-miRNA prognostic signature in OPSCC, as well as prognostic
signatures in other subtypes of HNSCC and within CESC, was developed using sequencing data
from TCGA as the primary source. This demonstrates the power of using TCGA as a potential
resource to develop prognostic tools for improving individualized patient care.

2.2

Introduction
Head and neck squamous cell carcinoma (HNSCC) constitutes approximately 3% of all

cancer diagnoses in the United States, with about 45,000 new cases in 2015 (2). Among head and
neck cancers, oral cavity, oropharyngeal and laryngeal cancers are the most common, accounting
for 24%, 23% and 27% of all diagnosed cases, respectively (3).
Due to the heterogeneity of these subtypes of HNSCC, a single prognostic signature
identifying high- and low-risk patients cannot be generated to cover all types of HNSCC.
However, multiple studies have indicated that individual biomarkers can stratify high-risk and
low-risk patients within the various subtypes (4-6). These biomarkers are not limited to coding
genes. Included among the proposed biomarkers are microRNAs (miRNAs), which are short
single-stranded RNA sequences (~22 n.t.) that function in post-transcriptional regulation. Further
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studies have shown that within oropharyngeal cancer, infection by human papillomavirus (HPV)
is a favorable prognostic marker (7). Greater prognostic power has been attained by combining
groups of biomarkers into a single signature for different subtypes of HNSCC, with various
degrees of success (8,9).
The other major cancer type associated with HPV infection is cervical cancer (CESC).
An estimated 528,000 new cases of cervical cancer worldwide are diagnosed annually, 95% of
which are caused by HPV (10,11). Cervical cancers can be further categorized by their tumor
source site, the majority of which can be classified as either cervical squamous cell carcinomas
(CSCC), or cervical adenosquamous carcinomas or adenocarcinomas (cervical adeno-type
cancers or CASC). As with oropharyngeal cancer, miRNAs have been examined as potential
biomarkers for determining patient prognosis, with several signatures having been published in
the literature (12,13).
The identification of novel biomarkers and subsequent development of prognostic
signatures requires in-depth analysis of genetic profiles. For example, high-throughput gene
expression profiling data have been made available by The Cancer Genome Atlas (TCGA), a
joint effort of the National Cancer Institute and the National Human Genome Research Institute
to provide a comprehensive set of patient genetic profiles across multiple cancer types (14). This
has extended to HNSCC, with a total of 529 HNSCC and 304 CESC samples being made
available (15,16). Included in the available data are RNA-seq and miRNA-seq profiles for the
majority of the provided patient samples.
In the current study, we investigated the prognostic value of miRNA biomarkers for
oropharyngeal squamous cell carcinoma (OPSCC), oral squamous cell carcinoma (OSCC), and
laryngeal squamous cell carcinoma (LSCC), using profiling data obtained from TCGA. These
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biomarkers were then used to develop unique prognostic signatures that robustly predicted
overall survival in the respective subsets of HNSCC. An additional signature was identified
through TCGA analysis for cervical cancer that maintained significance in both squamous cell
carcinoma (CSCC) and cervical adenosquamous carcinomas and adenocarcinomas (CASC). We
further demonstrate that use of the TCGA public dataset can provide a more general picture of
head and neck cancer as the prediction models obtained can be applied to an independently
obtained dataset. Through a combined analysis of TCGA data and independently generated data,
we have provided an additional set of biomarker tools for the clinical setting that can assist in
determining the best course of treatment for patients with head and neck cancer.

2.3

Materials and Methods

Retrieval of Public Data
A total of 523 anonymized patients in the TCGA database were identified as having primary
HNSCC. The clinical patient files were downloaded from TCGA Data Portal (tcgadata.nci.nih.gov). Of the 523 HNSCC patients, 82 patients had a primary tumor in the
oropharynx, 313 patients had a primary tumor of the oral cavity, and 115 patients had primary
tumors in the larynx. A total of 304 patients were identified as having primary CESC. Of the
307, 254 patients had a primary CSCC, 50 had a primary CACC, and 3 had a primary endothelial
carcinoma. A cutoff of five years was applied to all patient survival data.
All gene sequences were downloaded from the UCSC Genome Browser (17). Index files
mapping transcript accessions to NCBI Gene IDs were downloaded from the NCBI ftp site (18).
All mature miRNA sequences were downloaded from miRBase (19). Raw miRNA-seq data was
obtained for 81 of the 82 OPSCC patients, 311 of 313 OSCC patients, and all of the laryngeal
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cancer patients. Raw RNA-seq data was obtained for 72 of the 82 oropharyngeal cancer patients.
In the cervical cancer cohort, miRNA-Seq and RNA-Seq data were obtained for 227 CSCC
patients and 45 CACC patients. All raw RNA-seq and miRNA-seq files were downloaded
through the Cancer Genomics Hub (20).

TCGA Sequence Analysis
Sequence alignment was performed using the Bowtie program (21). Raw miRNA-seq
reads were aligned to the human miRNome. The read counts were then normalized to reads per
million reads mapped per sample and set to a floor value of 1 for lowly expressed miRNAs. Raw
RNA-seq reads were aligned sequentially to human RefSeq annotated sequences, the human
reference genome, and the virome. The read counts were normalized to reads per kilobase per
million mapped reads, then to the 2000th gene before being set to a floor of 5 normalized reads
for lowly expressed mRNAs. Both miRNA-seq and RNA-seq reads were subsequently log2
normalized.

Statistical Analysis for Survival and Correlation
Overall survival analysis was conducted using the ‘survival’ package in R (http://www.rproject.org). Correlation and covariance analysis was conducted in MATLAB (22). Univariate
Cox proportional hazards regression analyses were performed to evaluate the correlation
between individual miRNAs or mRNAs with overall survival. The p-values for outcome
correlation were calculated using the Wald test. The final prognostic signatures were also
evaluated in this manner. Multivariate Cox proportional hazards analyses were conducted to
evaluate the independent prognostic value of the miRNA signature after controlling for common

61

clinical variables. The Kaplan-Meier estimator was used to determine the empirical survival
probabilities and p-values from the log-rank test indicated the significance of the miRNA
prediction outcome model.

Collection of Independent Validation Data Sets
A total of 95 OPSCC cases were included in this study for validation. Patients were
treated at Washington University School of Medicine with definitive chemoradiation, or with
primary surgery followed by radiation therapy with or without chemotherapy. Clinical data were
collected from the patients and then updated retrospectively after follow-up review.
For all 95 of the patients, formalin-fixed, paraffin-embedded (FFPE) tumor tissues were
collected for pathological analysis before radiotherapy or chemotherapy. Sections from each case
were stained with hematoxylin and eosin and reviewed by a study pathologist at Washington
University to confirm the diagnoses. Tumor regions from each section were identified and
macrodissection was conducted. Total RNA was extracted from the identified tumor regions
using the miRNeasy FFPE kit (Qiagen) according to the manufacturer’s protocol. 66 patients
were used for the validation of the OPSCC miRNA prognostic model, and 39 patients for the
validation of the OPSCC mRNA model.

Quantitative Reverse Transcription PCR for miRNA model validation
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to
profile the miRNAs identified as significant in OPSCC and CESC. The details of this
experimental procedure have been described previously (23) . Briefly, the RT reaction was
performed with the High Capacity cDNA Reverse Transcription Kit (Life Technologies). Each
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RT reaction included 100 ng of tumor RNA and a pool of RT primers for selected miRNAs and
control RNAs. Quantitative PCR was performed with Power SYBR Green PCR Master Mix
(Life Technologies) and specific PCR primers for selected miRNAs or control RNAs. miRNA
raw profiling data for individual samples were normalized with four small RNA controls
(SNORD48, SNORD47, RNA5-8S5 and RNU6-1). Specifically, the expression levels of the four
small RNAs were averaged and used as the reference to control for sample variations during
miRNA profiling analysis.
The expression of p16 protein was determined by immunohistochemistry as previously
described (24). The expression profiles of E6 and E7 transcripts from six oncogenic HPV types
were determined by qRT-PCR, including types 16, 18, 33, 39, 56, and 59. The details of the HPV
assays and the experimental protocol have been described previously (24). In brief, primer
sequences for the assays were selected from the E6 and E7 coding regions of the high-risk HPV
genomes. The expression profiles of GAPDH and β-actin were used as reference controls for
data normalization.

2.4

Results

Validation of an existing miRNA prognostic signature
To verify that the miRNA data obtained from The Cancer Genome Atlas (TCGA) could
be used in further biomarker identification, we evaluated our previously published prognostic
model for OPSCC (9) with TCGA data. Briefly, this model identified miR-24-3p, miR-31-5p,
and miR-193b-3p as negatively associated with survival, and miR-26b-5p, miR-142-3p, and
miR-146a-5p as positively associated with survival. The expression levels of these 6 miRNAs
were then combined to create a single prognostic model as described previously (9):
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A
miRNA Name Fold change

P-value

miR-24-3p

0.08

0.62

miR-31-5p

0.14

0.11

miR-193b-3p

0.83

4.6E-03

miR-26b-5p

-0.33

0.097

miR-142-3p

-0.31

0.065

miR-146a-5p

-0.30

0.05

B

Figure 2.1. Validation of an existing miRNA signature with TCGA data. (A) The six miRNAs from
our previously published prognostic model for OPSCC were examined for association with the overall
survival of TCGA patients. Fold change values were log2 transformed and represent the average
expression difference of the miRNAs in the deceased patient group compared to the living patient
group. Statistical significance was determined with the logrank test in Cox regression analysis. (B)
Kaplan-Meier survival analysis to evaluate the prognostic performance of the six-miRNA signature
for predicting overall survival in OPSCC.

S = 2.62EmiR-24-3p + 3.16EmiR-31-5p + 2.45EmiR-193b-3p – 2.69EmiR-26b-5p – 3.34EmiR-142-3p – 2.81EmiR146a-5p
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We examined each miRNA individually with TCGA data and found that two miRNAs
were significantly associated with survival, two miRNAs maintained borderline significance
(p<0.1), and two miRNAs was not found to be significant (p>0.1) (Figure 2.1A). It should be
noted, however, that the directions of expression changes in relation to survival outcome were
maintained for all six miRNAs (i.e. positive correlations for miR-26b-5p, miR-142-3p, miR146a-5p, and negative correlations for miR-31-5p, miR-193b-3p, miR-26b-5p) (Figure 2.1A).
When we analyzed this prognostic model as whole, it was able to significantly differentiate
between high- and low-risk OPSCC patients from TCGA (Figure 2.1B). This demonstrated that
this previously published model was robust and could be applied to patient miRNA profiles
obtained from other institutions, while also indicating that the data from TCGA was a valuable
resource for further biomarker identification and analysis.

Unique TCGA miRNA expression profiles correlated with overall survival in OPSCC
miRNA expression analysis was performed for the 81 OPSCC patients obtained from TCGA.
The characteristics of these patients are summarized in Table 1. The miRNAs were examined
individually using Cox univariate proportional hazards analysis to determine which miRNAs
were correlated with overall survival. This analysis provides a log-rank p-value, which indicates
the significance of the miRNA in relation to survival, as well as a Wald coefficient, which
indicates the weight associated with the expression level of the miRNA.
We then implemented recursive feature elimination (RFE) technique to determine the
relative prognostic performance of individual miRNAs. In this process, a regression model was
generated using the given miRNA features and outcomes (i.e. miRNA expression and overall
survival, respectively), and the least impactful feature was eliminated. The process was then
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Table 2.1. Characteristics of the HNSCC patients included in TCGA.
OPSCC
OSCC
LSCC
CHARACTERISTICS
(n=81)
(n=311)
(n=115)
55.9 + 9.3
61.9 + 13.2
61.9 + 9.1
Age at diagnosis (mean + SD, y)
Sex
Male
69 (85.2%)
206 (66.2%)
95 (82.6%)
Female
12 (14.8%)
105 (33.8%)
20 (17.4%)
Race
White
75 (92.6%)
268 (86.2%)
91 (79.1%)
Other
6 (7.4%)
43 (13.8%)
24 (20.9%)
a
Smoking
Unreported
1 (1.2%)
10 (3.2%)
4 (3.5%)
Non-smoker
25 (30.8%)
88 (28.3%)
6 (5.2%)
Long-term former smoker
8 (9.9%)
51 (16.4%)
11 (9.6%)
Other former smoker
25 (30.9%)
68 (21.9%)
36 (31.3%)
Current smoker
22 (27.2%)
94 (30.2%)
58 (50.4%)
T classification
T1
13 (16.0%)
29 (9.3%)
7 (6.1%)
T2
36 (44.4%)
102 (32.8%)
20 (17.4%)
T3
20 (24.7%)
64 (20.6%)
33 (28.7%)
T4
12 (14.8%)
116 (37.3%)
55 (47.8%)
N Classification
NX
0 (0.0%)
4 (1.3%)
2 (1.7%)
N0
21 (25.9%)
142 (45.7%)
52 (45.2%)
N1
52 (64.2%)
52 (16.7%)
12 (10.4%)
N2
3 (3.7%)
110 (35.4%)
46 (40.0%)
N3
5 (6.2%)
3 (1.0%)
3 (2.6%)
Stage
I
5 (6.2%)
19 (6.1%)
2 (1.7%)
II
11 (13.6%)
62 (19.9%)
15 (13.0%)
III
12 (14.8%)
57 (18.3%)
18 (15.7%)
IV
53 (65.4%)
173 (55.6%)
80 (69.6%)
14 (17.2%)
109 (35.0%)
33 (28.7%)
Deceased
Abbreviations: OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral cavity squamous cell
carcinoma; LSCC, laryngeal squamous cell carcinoma; SD, standard deviation
a
Smoking was defined as no history of smoking, a former smoker of >= 15 years, other former smoker
of <15 years, or a current smoker.

repeated until the final iteration identified the most significant feature associated with the
classifier. This was performed on a subset of top-ranking 189 miRNAs in OPSCC ordered by
log-rank p-value while maintaining a Wald coefficient greater than or equal to one, and an
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average expression across all samples greater than 1.414 (i.e. a log2Expression of 0.5). In this
way, we were able to initially identify a set of promising miRNA candidates for further model
development.
In examining the 50 most significant miRNAs in accordance with the RFE, miR-193b-3p,
miR-455-5p, miR-92a-3p, and miR-497-5p were identified as maintaining a high RFE ranking
after 10-fold cross-validation, as well as being statistically significant in the univariate Cox

Figure 2.2. Four significant miRNAs associated with overall survival of TCGA OPSCC patients.
Fold change values were log2 transformed and represent the average expression difference of the
miRNAs in the deceased patient group compared to the living patient group. Significance was
determined with the logrank test in Cox regression analysis.
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proportional hazards analysis (Figure 2.2). All four of these miRNAs have been reported as
dysregulated in other cancer types, including colorectal cancer and pancreatic cancer (25-28).
We further confirmed the validity of miR-193b-3p as a prognostic marker in OPSCC, which we
had previously reported and incorporated in our previous model for outcome prediction (9).

A combined miRNA prognostic signature predicts overall survival in OPSCC
We further hypothesized that a combination of prognostic miRNAs within OPSCC could be
effectively used to predict overall survival. The miRNAs chosen in the aforementioned analysis
were used to build the following prognostic model:

SOPSCC = 11.31EmiR-193b-3p + 13.53EmiR-455-5p – 7.25EmiR-92a-3p – 7.3EmiR-497-5p,

where S indicates the risk score for each patient and E represents the normalized expression level
of the identified miRNA from the primary tumor. The coefficients in this equation are the Wald
scores from the Cox regression analysis and are representative of the relative importance of the
miRNA towards survival status.
In this prediction model, higher scores indicate higher risk and predict a poor survival
outcome for the patient. The patients were stratified internally by median risk score to produce 2
cohorts of similar size, so as to determine the validity of the prognostic model. By this method,
40 OPSCC patients were pre dicted to be high-risk (with > median score) and 41 patients were
predicted to be low-risk (i.e. with < median score); significantly different risks of death were
observed based on this classification (p = 6.8E-04) (Figure 2.3A).
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Figure 2.3. Kaplan-Meier survival analysis to evaluate the novel OPSCC 4-miRNA prognostic
signature. Patients were stratified into the low risk group or high risk group based on risk score. (A)
The signature was evaluated for overall survival in the training set from TCGA. Significance was
determined using the logrank test. (B) Leave-one-out cross-validation to evaluate the miRNA
modeling strategy. The cross-validated results from all rounds were combined for prognostic
evaluation of overall survival. (C) Independence of the miRNA signature in HPV(+) patients. (D)
Survival analysis to evaluate the miRNA signature for overall survival in the validation cohort.

One primary concern for prognostic model development is the risk of overtraining. To
address this issue, we performed leave-one-out cross-validation. For this cross-validation, within
each iteration, we removed one sample from the training set and trained a model with the
miRNA profiles from the remaining samples. The removed sample was then used for
independent model testing. The process was repeated until all the samples had been used
independently for model testing. For each validation round, the Wald coefficient for the
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candidate miRNAs were calculated based on the training set and used to generate a slightly
different model for testing. Cross-validation still yielded a significant separation of high- and
low-risk patients (Figure 2.3B), indicating that the model is robust within the training data.

The miRNA prognostic signature was independent of clinical features
We assessed if the miRNA signature maintained its prognostic value within the context of
commonly used clinical parameters, including age at diagnosis, gender, race, smoking history,
initial tumor staging, and treatment type. This analysis was conducted through multivariate Cox
hazards analysis. This miRNA signature was found to maintain statistical significance, with a
hazards ratio of 11.85 and p-value of 3.9E-03 (Table 2.2).

The OPSCC miRNA signature maintained its prognostic value independent of HPV status
Previous work has shown that HPV positivity is a favorable prognostic marker in
OPSCC, and thus we extended our miRNA signature to explore whether the prognostic
significance was maintained independently of HPV status. OPSCC patients were identified as
HPV-positive if sequencing reads from the RNA-seq data that did not align to the human

Table 2.2. Multivariate Cox regression analysis to evaluate independence of the prognostic miRNA
signatures from clinical parameters.
Parameter

a

OPSCC
HR
P-value a

OSCC
HR
P-value a

LSCC
HR
P-value a

miRNA signature

11.847

0.0039

1.88

1.8E-03

2.843

Age

1.056

0.054

1.017

6.1E-02

0.978

0.32

Sex

0.741

0.68

1.129

0.6

0.455

5.6E-02

Stage (I/II/III vs IV)

2.936

0.11

2.155

6.3E-04

1.013

0.91

Tobacco
Treatment (chemotherapy vs
radiotherapy vs combined)
Race (White vs. other)

1.386

0.31

1.052

0.54

1.17

0.40

0.637

0.034

0.906

0.96

0.866

0.17

7.906

0.11

0.919

0.95

2.369

2.6E-02

P-values were calculated using the Wald test.
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1.3E-02

Table 2.3. Characteristics of the OPSCC patients at Washington University
OPSCC miRNA validation
cohort (n=66)
58.5 + 10.2

OPSCC mRNA validation
cohort (n=39)
55.8 + 10.3

Male

54 (81.8%)

36 (92.3%)

Female

12 (18.2%)

3 (7.7%)

Age at diagnosis (mean + SD, y)
Sex

Race
White

65 (98.5%)

36 (92.3%)

Other

1 (1.5%)

3 (7.7%)

Smoking
Unreported

1 (1.5%)

4 (10.3%)

Non-smoker

22 (33.3%)

12 (30.8%)

Former smoker

27 (40.9%)

20 (51.3%)

Current smoker

16 (24.2%)

3 (7.7%)

T Classification
Tx

6 (9.1%)

6 (15.4%)

T1

28 (42.4%)

14 (34.9%)

T2

15 (22.7%)

9 (23.1%)

T3

7 (10.6%)

4 (10.3%)

T4

10 (15.2%)

6 (15.4%)

0 (0.0%)

6 (15.4%)

12 (18.2%)

2 (5.1%)

N Classification
NX
N0
N1

13(19.7%)

4 (10.2%)

N2

37 (56.1%)

24 (61.5%)

N3

4 (6.1%)

3 (7.7%)

Stage
Unreported

0 (0.0%)

6 (15.4%)

I

4 (6.1%)

1 (2.6%)

II

5 (7.6%)

0 (0.0%)

III

15 (22.7%)

5 (12.8%)

IV

42 (63.6%)

27 (69.2%)

10 (15.2%)

14 (35.9%)

Deceased

genome aligned to any of the 143 types of HPV. Of the 72 OPSCC patients with RNA-seq data,
46 were identified as having reads aligned to one of three types of HPV. Specifically, 39 patients
were positive for HPV16, four for HPV33, and three for HPV35, leaving 26 patients as HPVnegative.
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Of the 46 patients who were identified as HPV positive, 35 were identified as low-risk
and 11 as high-risk by the miRNA prognostic signature. Kaplan-Meier survival analysis
indicated that the high-risk group had poor survival as compared to the low-risk group (p = 7.9E03) (Figure 2.3C). The model was not statistically significant when applied to HPV-negative
patients (data not shown); however, it should be noted that the HPV-negative set was a much
smaller cohort (n=26), which significantly reduced the power of the model.

Validation of the OPSCC miRNA signature with an independent cohort
To confirm the validity of the 4-miRNA model for OPSCC prognosis, we applied our
miRNA signature to an independent cohort of 66 OPSCC patients treated at the Washington
University School of Medicine in St. Louis. The clinical characteristics of these patients are
outlined in Table 2.3. We hypothesized that the miRNA signature provides independent
prognostic value from HPV biomarker. Since HPV positivity is a favorable prognostic marker
for OPSCC, we were interested to know whether the new miRNA signature maintains its
prognostic value by further risk-stratifying HPV-positive patients.
All 66 patients were pre-selected to be p16 positive by immunohistochemistry, as p16 is a
robust surrogate biomarker for HPV expression (24). HPV expression in these tumors was
further validated by quantitative reverse-transcription PCR (qRT-PCR, see Methods for details).
Of the 66 tumors, 61 were HPV16 positive and two were HPV18 positive. HPV transcripts were
not detected in the remaining three samples.
Furthermore, qRT-PCR was conducted on the tumor samples for the four miRNAs
included in the signature. miRNA expression readings were normalized using four internal small
RNA controls (see Methods for details). The risk score was then calculated for each of these
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patients based on the miRNA signature. The patients were then stratified into high-risk and lowrisk groups by the median risk score. Kaplan-Meier survival analysis indicated that the miRNA
model was significantly predictive of survival outcome for the 63 HPV-positive cases (p = 1.6E03, Figure 2.3D). The miRNA signature had a similar prognostic performance when applied to
all 66 p16-positive cases (p = 2.8E-03).
We also analyzed the signature prediction scores with a receiver operating characteristic
(ROC) curve, which evaluated both the true positive rate (sensitivity) and the false positive rate
(specificity). In the training and validation sets, the areas under the curve were 0.84 and 0.84,
respectively, indicating robust performance of the model for both sensitivity and specificity
when applied to independent cohorts (Figure 2.4).

Unique miRNA expression profiles correlated with distinct subtypes of head and neck cancer
We extended our miRNA expression profiling analysis to the 311 OSCC and 115 LSCC
patients obtained from TCGA. The characteristics of these patients are summarized in Table 1.

Figure 2.4. Receiver operating characteristic (ROC) curves for the training and validation cohorts
from TCGA. The high Area Under the Curve (AUC) values indicate strong sensitivity and specificity.
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Table 2.4. Significantly dysregulated miRNAs associated with overall survival and used to develop
prognostic models for OSCC and LSCC, respectively.

OSCC

LSCC

miRNA name

Fold change a

p-value b

hsa-miR-337-3p

0.220

8.6E-04

hsa-miR-369-5p

0.428

5.5E-03

hsa-miR-218-5p

0.197

1.4E-02

hsa-miR-127-5p

0.381

7.0E-03

hsa-let-7a-3p

-0.710

5.2E-04

hsa-miR-145-5p

-0.440

6.2E-03

hsa-miR-129-5p

1.349

3.8E-02

hsa-miR-26b-5p
-0.333
8.4E-03
a
Fold change is log2 normalized.
b
P-values are from the logrank score from Cox univariate analysis.

For each additional subtype of HNSCC, we conducted similar analyses as described for OPSCC
and identified 4 miRNAs in each subset that were predictive of overall survival (Table 2.4).
These miRNAs were then combined to generate the following prognostic models:

SOSCC = 10.73EmiR-337-3p + 7.82EmiR-369-5p + 6.21EmiR-218-5p + 7.01EmiR-127-5p,

SLSCC = –10.70Elet-7a-3p - 6.96EmiR-145-5p + 4.59EmiR-129-5p – 6.43EmiR-26b-5p,

As described earlier, the median score was used within each subset to separate patients
into high- and low-risk groups, which were also found to have significantly different risks of
death (p = 1.8E-04 in OSCC and p = 2.4E-03 for LSCC) (Figures 2.5A and B). We also
conducted leave-one-out cross-validation analysis for these two signatures and found a
significantly different risk of survival in the miRNA-stratified groups of OSCC and a borderline
significance for LSCC (Figures 2.5C and D). Despite borderline significance of the LSCC model
in cross-validation analysis, the LSCC prognostic miRNA model may still be useful for
prediction of patient survival. In particular, these models maintained statistical significance
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C

D

Figure 2.5. Kaplan-Meier survival analysis to evaluate the OSCC and LSCC miRNA prognostic
models. (A, B) The models were evaluated in the respective training sets. (C, D) Leave-one-out crossvalidation results were combined for prognostic evaluation.

independently of clinical features when analyzed with multivariate Cox analysis, with the OSCC
model having a hazards ratio of 1.88 and a p-value of 1.8E-03, and the LSCC model having a
hazards ratio of 2.84 and a p-value of 1.3E-02 (Table 2.2).
It is noteworthy that each miRNA signature carried prognostic significance when applied
to the HNSCC subtype where it was derived. On the other hand, when applied to other subtypes
of HNSCC, none of the signatures were able to effectively distinguish high-risk and low-risk
patients (Figure 2.6). We also observed this phenomenon when we applied the
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D

Figure 2.6. Kaplan-Meier survival analysis to evaluate the miRNA prognostic signatures in other
subtypes of HNSCC. (A, B) Survival analysis of the OPSCC miRNA signature in OSCC (A) and
LSCC (B). (C, D) Survival analysis of the OSCC miRNA signature in OPSCC (C) and LSCC (D). (E,
F) Survival analysis of the LSCC miRNA signature in OSCC (E) and LSCC (F).
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A

B

Figure 2.7. Kaplan-Meier survival analysis to evaluate an existing OPSCC miRNA signature in
OSCC (A) and LSCC (B).

previously developed 6-miRNA prognostic model to OSCC and LSCC (Figure 2.7). In
conjunction with previous studies indicating significant genetic heterogeneity between subtypes
of HNSCC (15), our results indicate that the miRNome is just as unique for each HNSCC
subtype.

Cervical cancer miRNA signatures maintain significance across tumor source sites
The Cancer Genome Atlas also provided samples for cervical cancer. We were able to
analyze 276 total cancers that were identified to have sufficient miRNA-Seq results and
appropriate follow-up data (Table 2.5). Through similar analyses, we first aimed to validate a
previously described survival signature for cervical cancer based on 2 miRNAs (12):

S = 17.9 – 0.284EmiR-9-5p – 0.376EmiR-200a-3p,

where 17.9 was chosen as the zeroing coefficient. Given the change in quantification platforms
from qRT-PCR to RNA-Seq, the signature was modified by removing the coefficient and using
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Table 2.5. Characteristics of the CESC patients included in TCGA.

48.2+13.9

Squamous Cell
Carcinoma
(n=227)
48.7+14.2

Adenocarcinoma and
Adenosquamous Cell
Carcinoma (n=45)
45.1+12.2

Median follow up time (days)

469

471

306

Race
White

CHARACTERISTICS

Total Cervical
Cancer (n=276)

Age at diagnosis + SD

197

158

35

Black or African American

28

26

2

Other

22

19

3

Unreported

29

24

5

254

216

37

137

109

24

Long-term former smoker

8

7

1

Other former smoker

42

34

8

Current smoker

60

51

9

Unreported

29

26

3

T classification
TX

17

15

2

HPV (+)
Smokinga
Nonsmoker

Tis

1

1

0

T1

131

103

26

T2

63

51

11

T3

17

14

2

T4

10

9

1

Unreported

37

34

3

N classification
NX

65

54

10

N0

122

95

24

N1

52

44

8

N2

0

0

0

N3

0

0

0

Unreported

37

34

3

Stage
I

152

117

33

II

61

55

5

III

37

34

2

IV

20

15

5

Unreported

6

6

0

Deceased in study

63

53

10

a

Smoking was defined as no history of smoking, a former smoker of >= 15 years, other former smoker
of <15 years, or a current smoker.
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Low risk (n=138)
High risk (n=138)

Figure 2.8. Kaplan-Meier survival analysis to analyze an existing 2-miRNA prognostic signature in
cervical cancer.

the median scores across all TCGA samples as the cutoff value to distinguish high- and low-risk
groups. The trend was accurate, but was unable to reach statistical significance (Figure 8).
We then aimed to develop a novel miRNA-expression prognostic signature, using TCGA
as the primary training set. The analysis identified four miRNAs as statistically significant for
survival: miR-361-3p, miR-532-3p, and miR-150-5p are positively associated with survival, and
miR-335-3p is negatively associated (Table 2.6). By using the z-scores obtained from univariate
Cox survival analysis as coefficients, the resulting signature is as follows:

Table 2.6. Significantly dysregulated miRNAs associated with overall survival and used to develop
prognostic models for CESC.
miRNA name

Fold change a

P-value b

z-score

hsa-miR-361-3p

-0.481

3.8E-07

-5.08

hsa-miR-532-5p

-0.514

8.7E-05

-3.92

hsa-miR-150-5p

-0.911

2.7E-03

-4.90

hsa-miR-335-3p
0.544
1.8E-02
Fold change is log2 normalized.
b
P-values are from the logrank score from Cox univariate analysis.
a
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Low risk (n=139)
High risk (n=137)

Low risk (n=138)
High risk (n=138)

Figure 2.9. Kaplan-Meier analysis for a novel 4-miRNA prognostic signature in cervical cancer. The
model was evaluated in (A) the training data from TCGA and (B) with 10-fold cross-validation.
Significance is determined using the logrank p-value from Cox univariate survival analysis.

S = -5.08EmiR-361-3p – 3.92EmiR-532-3p – 4.90EmiR-150-5p + 3.00EmiR-355-3p

In the training data, this signature was confirmed to significantly separate high-risk and low-risk

Figure 2.10: The receiver operating characteristic (ROC) curve for the novel CESC signature in the
TCGA training cohort. The area under the curve was 0.716.
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Low risk (n=24)
High risk (n=21)

Low risk (n=115)
High risk (n=112)

Figure 2.11: Kaplan-Meier analysis for the novel CESC signature in (A) cervical squamous cell
carcinomas and (B) cervical adenosquamous carcinomas and adenocarcinomas. Significance is
determined using the logrank p-value from Cox univariate survival analysis.

patients (p = 8.6E -07) without overtraining, as shown in 10-fold cross-validation (1.8E-06)
(Figures 2.9A and B). ROC analysis also indicated model robustness in the context of sensitivity
and specificity, with an area under the curve of 0.716 (Figure 2.10). More importantly, KaplanMeier analysis also showed that this signature was able to distinguish between high-risk and lowrisk patients in both squamous cell carcinomas and adeno-type carcinomas. High-risk and lowrisk cohorts in the squamous cell patient group were separated with a p-value of 1.9E-05, and in
the adeno-type carcinomas with a p-value of 9.5E-03 (Figure 2.11). However, this signature
could not be validated in an independent cohort of 59 cervical cancer patients treated at
Washington University, likely due to significant patient-to-patient variations from different
cohorts or treatment regimens (Figure 2.12).
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Low risk (n=29)
High risk (n=29)

Figure 2.12: Kaplan-Meier analysis of the novel CESC signature in an independent cervical cancer
cohort. Significance was determined using the logrank test from univariate Cox survival analysis.

2.5

Discussion
Identification of novel prognostic biomarkers typically requires a large dataset which

provides sufficient statistical power for discovery research. To this end, we took advantage of
the high-throughput data from TCGA for biomarker analysis. The TCGA consortium has
published many studies identifying the mutations and dysregulations associated with tumors in
comparison to matched normal tissue samples. There are also a number of studies that used
TCGA data for independent validation of existing biomarkers (13,29,30). Additionally, many
studies exploring miRNA biomarkers in head and neck cancer, including the miR-34 family and
miR-200a species, have indicated their roles in oncogenesis (31). However, few studies have
utilized TCGA data in systematically identifying biomarkers associated with patient outcome.
In this study, we have presented a new strategy to identify prognostic miRNA biomarkers
by analyzing TCGA data directly, followed by experimental validation using an independent
cohort. As the first step, we utilized TCGA data as the primary source to identify biomarkers
and develop prognostic models for OPSCC. Within OPSCC, infection by HPV has already been
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indicated as a favorable prognostic factor (7). Our model was able to further improve the
prognostic value of HPV positivity by identifying a high-risk cohort among HPV(+) patients.
Next, we were able to validate the robustness of this signature using an independent cohort that
consisted only of HPV(+) OPSCC patients. This confirmed that the miRNA signature was able
to further distinguish high- and low-risk patients within HPV(+) OPSCC patients.
Among the subtypes of HNSCC, OPSCC has unique characteristics as HPV infection is
associated with most OPSCC cases. Although the total number of HNSCC cases has decreased
steadily on a yearly basis, the number of reported OPSCC cases has increased significantly as a
result of rapid rise in HPV(+) OPSCC cases (32,33). Our clinical goal of building a powerful
prognostic model is to reliably stratify OPSCC patients for treatment failures after standard
therapy. The availability of such a reliable prognostic model is critical for providing
individualized cancer therapy, including both de-intensifying treatment for low-risk patients as
well as intensification for high-risk patients. In particular, there is currently significant clinical
interest in identifying a subset of OPSCC patients who have low-risk of treatment failures, in
order to de-intensify their overall treatment. As present, multi-institutional de-escalation clinical
trials are underway for HPV(+) OPSCC patients (34,35). However, there is still a significant
portion of HPV(+) OPSCC cases that have poor outcome. For these cases, de-escalation
treatment should not be applied and instead the treatment should be intensified. Thus, there is a
critical need to develop robust prognostic models to further stratify HPV(+) OPSCC patients for
enrollment in de-escalation trials. To this end, our proposed miRNA-based prognostic model will
fill in a critical need by selecting HPV(+) OPSCC patients who will most likely benefit from deescalation treatment. Further work would be required to bring this signature fully to the clinical
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setting, such as the inclusion of reference genes to standardize the signature score and allow
clinicians to determine the appropriate treatment modality.
Our analysis involving cervical cancer demonstrated that the methods for identifying
miRNA biomarkers in TCGA data, or other large public –omics datasets, can be extended
beyond head and neck cancers. The signature we described was robust within the training data
from TCGA, as demonstrated through cross-validation and ROC analysis, but was unable to
maintain significance in an independent dataset. Despite this drawback, it was notable that the
signature was able to separate high- and low-risk patients across cervical cancer species. It has
been noted in the literature that patients with adeno-type cervical carcinomas are genetically
distinct from squamous type carcinomas, as well as conferring higher risk (16,36). Therefore, the
possibility of using a single prognostic signature to stratify patients prior to determination of
tumor source in cervical cancers merits further investigation. Additional work in this field would
incorporate more individualized approaches, as genomic heterogeneity may also require unique
miRNomic profiles for the differing cervical tissues.
Besides OPSCC, we have also shown that our strategy on TCGA-based biomarker
discovery can be extended to the study of other subtypes of HNSCC, as well as CESC. In this
way, we have demonstrated that TCGA represents a rich resource for cancer prognostic studies.
We expect that prognostic tools developed using TCGA data, with proper validation, will
significantly expand our ability to more precisely manage cancer patients by applying
individualized treatment plans.

2.6
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Chapter 3: Development of an Online
Resource for Exploring Pan-Cancer
MicroRNA Dysregulation
This chapter is adapted from and expanded upon the following publication (1):
Wong, Nathan, Yuhao Chen, Shuai Chen and Xiaowei Wang. (2017). OncomiR: An online
resource for pan-cancer microRNA dysregulation. Bioinformatics, btx627. DOI:
10.1093/bioinformatics/btx627.

3.1

Abstract

Dysregulation of microRNAs (miRNAs) is extensively associated with cancer development and
progression. miRNAs have been shown to be biomarkers for predicting tumor formation and
outcome. However, identification of the relationships between miRNA expression and tumor
characteristics can be difficult and time-consuming without appropriate bioinformatics expertise.
To address this issue, we present OncomiR (http://oncomir.org), an online resource for exploring
miRNA dysregulation in cancer. Using combined miRNA-Seq, RNA-Seq, and clinical data from
The Cancer Genome Atlas, we systematically performed statistical analyses to identify
dysregulated miRNAs that are associated with tumor development and progression in most major
cancer types. Additional analyses further identified potential miRNA-gene target interactions in
tumors. These results are stored in a backend database and are presented through a web server
interface. Moreover, through a backend bioinformatics pipeline, OncomiR can perform dynamic
analysis with custom input data for in-depth characterization of miRNAs in cancer.
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3.2

Introduction

MicroRNAs (miRNAs) are short, single-stranded RNA sequences of approximately 22
nucleotides that function in post-transcriptional regulation of gene expression. By targeting RNA
transcripts for degradation or inhibition of translation, miRNAs are actively involved in
controlling downstream proteomic profiles. This phenomenon is observed in numerous
physiological or disease processes, such as embryonic development, tissue differentiation,
immune response, and tumor progression (2). Furthermore, miRNAs can serve as biomarkers for
various diseases, with particular clinical interest in predicting likelihood of cancer development
and progression.
miRNA biomarkers have been discovered in nearly all cancer types. For example, in
breast cancer, miR-21-5p and miR-155-5p, among others, have been reported as upregulated as
compared to normal tissue, while miR-34a-5p and miR-145-5p are downregulated (3). However,
it has also been noted that miR-221-3p and miR-222-3p are both downregulated in erythroblastic
leukemia but upregulated in in thyroid carcinoma and hepatocellular carcinoma, which suggests
that the mechanisms driving tumor formation and progression are not uniform across all cancer
types (3) . The majority of studies that identify miRNA biomarkers focus on a single or a subset
of miRNAs; however, with the growth of affordable high-throughput sequencing technologies, it
is possible to analyze the complete miRNomes from many patients across multiple cancer types.
Analysis of high-throughput data is difficult for researchers with little computational
expertise. To address this issue, a number of databases have been previously established to
characterize miRNA functions in cancer. For example, miRCancer, miR2Disease, and
OncomiRDB present experimentally validated relationships between miRNA expression and
cancer development, based on literature reports (4-6). Other resources, including starBase,
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cBioPortal and FireBrowse, among others, provide results of statistical analyses on highthroughput sequencing studies of cancer genomics as a whole, but not specifically focused on
miRNA analysis (7-11).
Incorporating all the facets of miRNA biology into a comprehensive user-friendly toolset
is a daunting task, as it requires identifying potential miRNA biomarkers and their targets as well
as establishing their functional relationships in the context of cancer biology. To address this
need, we present OncomiR, an online pan-cancer resource for analysis of miRNA dysregulation.
OncomiR contains three major features: 1) A database of statistically dysregulated miRNAs
associated with clinical characteristics of cancer; 2) miRNA-target expression correlation and
prediction across cancer types; and 3) tools for dynamic analysis of miRNA-derived survival
signatures and clustering of cancer types. The diverse functionality of OncomiR would make it a
valuable resource to the miRNA and cancer research community.

3.3

Materials and Methods

Data Retrieval
Anonymized patient clinical data, normalized mature miRNA-Seq read counts, and normalized
RNA-Seq read counts were obtained from The Cancer Genome Atlas data portal (tcgadata.nci.nih.gov, gdc-portal.nci.nih.gov). Patients were excluded from subsequent analysis if the
clinical data indicated no follow up time, the tissue specimens were not obtained from primary
tumors, or the sample lacked either miRNA-Seq or RNA-Seq data. In total, 9,498 patients were
analyzed across 30 cancer types (Table 3.1). miRNA-Seq read counts less than 1 read per million
reads mapped (RPM) were fixed to a floor value of 1 RPM and log2 transformed. RNA-Seq read
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counts less than 5 reads per kilobase per million reads mapped (RPKM) were fixed to a floor
value of 5 RPKM prior to log2 transformation.

Data Analysis
Patient survival time is defined as the days between the start of treatment and the most
recent follow up appointment or patient death. Follow up time was truncated to five years in
order to determine the five-year survival status.
Table 3.1. Summary of cancer types and patient counts from The Cancer Genome Atlas.
Cancer Type (abbreviation)

80
412
515
1098

Patients analyzed
(patients excluded)
80 (0)
407 (5)
508 (3)
1065 (33)

308

289 (19)

36
459
185
528
66
536
291
377
521
504
87
585
185
179
498
171
261
570
443
150
507
124
548
57
80

36 (0)
424 (35)
184 (1)
522 (6)
65 (1)
514 (22)
288 (3)
366 (11)
500 (21)
472 (32)
86 (1)
484 (101)
177 (8)
179 (0)
494 (4)
155 (16)
259 (0)
96 (474)
413 (13)
134 (16)
505 (2)
123 (1)
536 (12)
56 (1)
80 (0)

10,361

9,497 (864)

Total patients

Adrenocortical carcinoma (ACC)
Bladder urothelial carcinoma (BLCA)
Brain lower grade glioma (LGG)
Breast invasive carcinoma (BRCA)
Cervical squamous cell carcinoma and endocervical
adenocarcinoma (CESC)
Cholangiocarcinoma (CHOL)
Colon adenocarcinoma (COAD)
Esophageal carcinoma (ESCA)
Head and neck squamous cell carcinoma (HNSC)
Kidney chromophobe (KICH)
Kidney renal clear cell carcinoma (KIRC)
Kidney renal papillary cell carcinoma (KIRP)
Liver hepatocellular carcinoma (LIHC)
Lung adenocarcinoma (LUAD)
Lung squamous cell carcinoma (LUSC)
Mesothelioma (MESO)
Ovarian serous cystadenocarcinoma (OV)
Pancreatic adenocarcinoma (PAAD)
Pheochromocytoma and paraganglioma (PCPG)
Prostate adenocarcinoma (PRAD)
Rectal adenocarcinoma (READ)
Sarcoma (SARC)
Skin cutaneous melanoma (SKCM)
Stomach adenocarcinoma (STAD)
Testicular germ cell tumor (TGCT)
Thyroid carcinoma (THCA)
Thymoma (THYM)
Uterine corpus endometrial carcinoma (UCEC)
Uterine carcinosarcoma (UCS)
Uveal melanoma (UVM)
Total
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Paired tumor and non-tumor samples were obtained from 670 patients in the data set. The
relationship between tumor formation and miRNA expression within these cancer types were
evaluated using paired Student’s t-test. For each clinical feature, analysis of variation (ANOVA)
was used to determine the association between miRNA expression and relevant feature values.
Survival analysis was performed using Cox proportional hazards analysis. Univariate analysis
was conducted to determine the influence of the expression of a single miRNA on survival time;
multivariate analysis was implemented to determine if the effect of the miRNA was independent
of clinical characteristics. Additionally, the unpaired Student’s t-test was employed to evaluate
the difference in the average miRNA expression between living and deceased patients.
The likelihoods of miRNA-gene target pairings were evaluated using Pearson’s
correlation analysis based on the expression profiles of both miRNAs and mRNAs, in
conjunction with target prediction scores obtained from miRDB (12). For each individual cancer
type, all available tumor samples were incorporated in the correlation analysis. Additionally, all
paired tumor/normal tissue types were evaluated as a single set, so as to provide a miRNA-target
interactome specific to tumor formation by comparing to normal tissues. All statistical analysis
was conducted using the R statistical program (www.r-project.org).

3.4 Results
Database and Web Server Construction
OncomiR consists of a primary backend database and a dynamic web server. Results from the
statistical analyses are stored in a MySQL database accessible through Perl CGI and Perl DBI
(Figure 3.1A). The OncomiR web server implements Perl CGI in conjunction with the R
statistical program in order to conduct ad hoc backend analysis (Figure 3.1B).
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A

B

Figure 3.1. Database and server design for OncomiR. (A) The OncomiR database contains the results
of statistical analysis of miRNA expression in relation to patient characteristics for biomarker
identification, and with mRNA expression to identify potential gene targets. (B) The OncomiR web
server can perform de novo analysis for miRNA survival signatures and miRNA expression-based
clustering for most cancer types.

The primary database design uses keys based on miRNA accession, cancer type, gene GI,
and clinical diagnostic parameter (Figure 3.2). The resulting combinations can be used to search
for: miRNAs associated with tumor formation; miRNAs dysregulated between cancer diagnostic
stages; miRNAs correlated patient overall survival in individual cancer types; average miRNA
expression levels in cancers; and miRNA-target interactions specific to cancer types.
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Figure 3.2. Database schematic for OncomiR. Each box represents an individual table in the
OncomiR database. Arrows indicate the keys used by MySQL database. Arrow sources show the
home tables of the key, and the destinations show how the keys can be used in combination for rapid
data retrieval.

miRNA Dysregulation in Cancer Development and Progression
The identification of novel RNA-derived molecular biomarkers in the clinical setting
requires a combination of high-throughput data, such as next-generation sequencing, and robust
statistical analysis. With this in mind, we have conducted such analyses using miRNA-Seq data
from TCGA and evaluated the significance of miRNA expression in relation to clinical
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parameters. The results of these studies have been included in OncomiR, encompassing 30 major
cancer types and 1,171 distinct mature miRNA sequences.
OncomiR features a web query interface for the retrieval of miRNA associations to three
primary clinical features: tumor development, tumor staging and grade, and overall patient
A

B

Figure 3.3. Search for miRNA biomarkers in the OncomiR database. A screenshot of a miRNA
search in relation to clinical parameters (A) produces a table of results containing the miRNA and
related cancer types, and p-values from relevant statistical tests (B).
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survival. For all there categories, users can search by miRNA name as assigned in miRBase
Release 21 (13); users are also able to filter results by selecting one or more cancer types (Figure
3.3A). In this way, users can retrieve lists of miRNAs associated with specific clinical features
in selected tumor types.
The results are presented in a tabular format, where each row shows the paired miRNA
and specified cancer types and clinical features, with relevant statistics indicating the
significance of the miRNA interaction. A screenshot of search results for diagnostic parameters
associated with a specific miRNA is shown in Figure 3.3B: each row in the results shows the
miRNA, cancer type, diagnostic criteria, and relevant p-values. Such results are similar across
different search parameters. For example, searching for miRNAs associated with survival in
different cancer types will return a list of miRNAs, with raw and adjusted p-values from
unpaired Student’s t-test comparing expression between living and deceased patients, as well as
univariate Cox proportional hazards analysis, which includes survival time as a factor (Figure

Figure 3.4. Search results for survival-associated miRNAs. Results indicate the relevant miRNAs in a
given cancer type, their associated statistical significance with survival, and the cohort in which the
miRNA is upregulated.
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Figure 3.5. Search results for average miRNA expression levels. The results are presented in the form
of log2 mean expression in each cancer type, as well as a bar graph for a visual comparison of mean
expression.

3.4).
OncomiR also offers the users to compare the mean expression values of miRNAs across
two or more cancer types. When selecting a single miRNA, the results are presented both as a
table of mean values and as a bar graph (Figure 3.5), while a search for multiple miRNAs will
produce a table containing the search results.

miRNA-Target Prediction for Tumor Samples
Since miRNAs function as post-transcriptional regulators of gene expression,
dysregulation of miRNAs implies that downstream regulation of mRNA targets would also be
affected. To address this within the context of cancer biology, OncomiR offers the ability to
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search for significant expression correlations between miRNAs and potential gene targets in
tumor samples. The likelihood of a miRNA targeting a specific transcript is dependent on
multiple features, such as the miRNA seed sequence (nucleotides 2-8) and target site
accessibility. OncomiR combines the results of expression correlation analysis between miRNAs
and mRNAs with the results of the recently updated MirTarget algorithm (version 3) to identify
likely targeting effects within specific cancer types (14). All target prediction data were retrieved
from miRDB.org (12).
Users are able to search for potential interactions by querying either for miRNA or gene
target and selecting one or more cancer types. The inclusion of cancer types as a search
parameter is necessary, considering the genomic heterogeneity between different tissues. Each
miRNA-target pair within the set is presented with the correlation coefficient and p-value from
Pearson’s correlation analysis, along with MirTarget prediction score, as obtained from miRDB
(Figure 3.6). The most likely miRNA-target pairs have both strongest negative correlation

Figure 3.6. OncomiR search results for miRNA target prediction. The paired miRNA-target
interactions are evaluated in individual cancer types for directional correlation and prediction score,
obtained from the MirTarget algorithm.
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coefficients among the tumors and highest target prediction scores by MirTarget. The selection
criteria can be further loosened to include more miRNA-target pairs that have lower Pearson’s
correlations or MirTarget scores.

Server Interface for Custom miRNA Analysis
One of the most significant clinical applications of cancer biomarker research is the
stratification of patients for individualized therapy based on treatment outcome. To make our
analysis more accessible to the clinical research community at large, OncomiR can analyze
miRNA-derived survival outcome signatures dynamically for one or more cancer types. Users
are able to input their selected miRNAs with pre-determined coefficients, as well as a percentile
cutoff to determine the sizes of high- and low-risk cohorts (Figure 3.7A). The coefficient options
also include using raw miRNA expression levels, or using z-scores resulting from a preliminary
univariate Cox proportional hazards analysis. The results are presented in the form of a KaplanMeier survival curve and the logrank p-value to indicate the significance of cohort separation
(Figure 3.7B). This feature is particularly useful for the evaluation of new biomarker signatures
discovered with TCGA data, or validation of existing signatures derived from other independent
studies.
Another feature of OncomiR is the ability to dynamically cluster major cancer types by
miRNA expression. To this end, OncomiR offers dynamic clustering, whereby users can
evaluate the suitability of using miRNA subsets to distinguish different cancer types. The mean
expression of each miRNA was calculated within the individual cancer types; this average
miRNomic profile can then be used as the basis of k-means or hierarchical clustering. (Figure
3.7C). Briefly, k-means clustering requires a predetermined number of groups, or clusters, into
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which patients are sorted on the basis of expression similarity; hierarchical clustering initially
treats each sample as its own individual cluster and builds a dendrogram by connecting clusters
that are most closely related (15). Both clustering options return a list of cancer types that cluster
A

C

B

D

Figure 3.7. De novo analysis in OncomiR for survival signature and tumor clustering. (A) Survival
analysis is conducted by selecting one or more cancer types, a list of miRNAs, and a list of
coefficients. (B) The results of survival analysis are shown as a Kaplan-Meier curve. (C) Clustering of
cancer types can be conducted using all miRNAs or a user-defined subset of miRNAs. (D) An
example of hierarchical clustering is shown as a heat map.
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together, and hierarchical clustering also produces a heatmap to visualize the similarities and
differences between clusters (Figure 3.7D).

3.5

Discussion
The identification of novel molecular biomarkers often requires comprehensive high-

throughput datasets that are sufficiently large to minimize potential noise from patient-to-patient
variations while also being thoroughly inclusive of less well-studied genes. Through TCGA, we
obtained high-throughput miRNA-Seq and RNA-Seq data across 30 cancer types, with
corresponding clinical profiles from thousands of patients. To systematically analyze miRNArelated TCGA data, we established a comprehensive bioinformatics pipeline to evaluate miRNA
expression changes in relation to various clinical parameters such as tumor staging and patient
survival status. In this way, we identified many dysregulated miRNAs involved in tumor
formation, progression, and survival, and we have presented these results in OncomiR, a web
accessible database.
By focusing primarily on miRNAs and miRNA-mediated biological functions, OncomiR
can provide a greater insight into the miRNomic effects on tumor biology. Navigating OncomiR
for miRNA biomarkers is designed to be both intuitive and informative. Users are able to select
a preliminary search criterion, and navigate through a single search to find the desired results. In
addition, flexible options are provided for more advanced analyses. In combination, these
analyses can identify dysregulated miRNAs and targets in specific tumor types, and subsequently
suggest potential pathways involved in the observed clinical phenomena, such as metastatic
staging or overall survival. Multiple well-established miRNAs have been rediscovered through
our analyses as being involved in cancer, consistent with previously reported studies. For
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example, miR-92a-3p functions as an oncogenic miRNA, i.e. is overexpressed in tumor tissue as
compared to normal tissue (16). More importantly, many new miRNA/cancer associations have
been identified through our systematic analysis, especially in the context of specific cancer types.
These new data provide useful clues for further characterization of miRNA functions in various
types of cancer.
By incorporating the R statistical program, OncomiR performs clustering analysis of
most known cancer types based on miRNA expression profiles. Subsets of miRNAs may be able
to provide insight into similarities between cancer types. For example, our miRNA clustering
analysis reveals that two subtypes of lung cancer, lung adenocarcinoma (LUAD) and lung
squamous cell carcinoma (LUSC) cluster together as expected, while a less intuitive similarity is
observed as prostate adenocarcinoma (PRAD) clusters with three subtypes of kidney cancer
(chromophobe, KICH; renal cell carcinoma, KIRC; and renal papillary carcinoma, KIRP)
(Figure 3.7D). By evaluating the similarities as well as differences in miRNA expression in
various cancer types, a greater understanding of how these cancers, and by extension, their
original tissue sources, could in turn lead to improved clinical interpretations and subsequent
interventions.
Currently, the strength of OncomiR lies in its ability to identify significant miRNAs
based on clinical parameters shared across multiple cancer types, such as diagnostic staging and
patient survival (Figure 3.8). Future updates of the database would benefit greatly from
identifying biomarkers associated with cancer-specific traits. One example is the association of
miRNAs with oncogenic viral infection, such as human papillomavirus in cervical and
oropharyngeal cancers or hepatitis infection leading to liver cancer (17-19). Additional work
may also include potential pathways mediated by miRNA dysregulation. Tools for analyzing
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Figure 3.8. Overview of OncomiR’s functionality. The data was obtained from TCGA and
analyzed before being stored in a backend database. The database is accessible through a web
interface that allows users to search for and identify miRNAs associated with cancer
classification and clinical diagnostic parameters.
comprehensive gene sets, as compared to individual genes, include PANTHER and Gene Set
Enrichment Analysis (20,21). Such studies would be conducted on the gene transcripts regulated
directly by the dysregulated miRNAs, as shown in the current target analysis results.
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In summary, OncomiR is a user-friendly web resource for exploring miRNA
dysregulation in cancer. We have conducted statistical analyses on miRNomes from TCGA to
provide a readily accessible repository of miRNA associations with cancer characteristics.
Additionally, correlation and target analysis were conducted to provide insights into possible
miRNA-mediated mechanisms leading to cancer development and progression. Moreover,
OncomiR also provides a set of dynamic tools for researchers to conduct custom miRNA
analyses. Thus, OncomiR is a comprehensive tool that allows and encourages flexible
miRNomic analysis across many cancer types.
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Chapter 4: Pathway Analysis Identifies
MicroRNA-Mediated Mechanisms of HPVInduced Oncogenesis and Tumor Survival
4.1

Abstract
Human papillomavirus (HPV) is the primary cause of 95% of new cervical cancer

diagnoses and 75% of new oropharyngeal cancer diagnoses. Despite its role in causing tumor
formation, HPV is also established as a positive prognostic marker for tumor survival. Through
infection HPV can induce expression changes in the host transcriptome, as well as regulatory
elements such as microRNAs (miRNAs). The responsiveness of regulatory elements, such as
those controlled by miRNAs, may explain the tumorigenic/pro-survival dichotomy of HPV
infection. To determine how these effects are induced from both the host miRNome and host
transcriptome, we have identified HPV infection status in 301 cervical cancers and 79
oropharyngeal cancers obtained from The Cancer Genome Atlas. Based on HPV status, we
performed comprehensive statistical analysis to identify dysregulated miRNAs and gene
transcripts. Potential gene targets were subjected to pathway analysis using the PANTHER
database, so as to observe the cumulative effects in the context of Gene Ontology-defined
biological processes. Pathway analysis revealed that significantly upregulated genes in both
HPV(+) and HPV(-) tumors favored cellular reproduction and growth processes; HPV(-) tumors
indicated underrepresentation of cellular adhesion pathways, which hint at possible mechanisms
for tumor migration and poorer survival. More focused miRNA-target analysis showed
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upregulation of both tumor suppressors and oncogenes, indicating that miRNA mediation may
partly explain the dichotomy of HPV infection inducing tumor formation yet encouraging overall
patient survival.

4.2

Introduction
With his Nobel Prize winning hypothesis that human papillomavirus is a correlative, and

ultimately causative, factor in cervical cancer, Harald zur Hausen demonstrated that cancer may
not only be treated after diagnosis, but that the potential existed that if the cause is known, cancer
as a disease may also be preventable (1,2). In the years since, research has shown that the
primary mechanisms of HPV-induced oncogenesis are based in the activities of the E6 and E7
viral proteins. E6 induces the ubiquitination of the regulatory protein p53, which is also known
to function as a tumor suppressor (3). At the same time, E7 binds to and inactivates the tumor
suppressor pRB, which in turn leads to the release of the transcription factor E2F1, which
controls for a number of transcription factors associated with cell growth and proliferation (4).
HPV has also been shown to induce alteration in the expression profiles of microRNAs
(miRNAs), short non-coding RNA transcripts of approximately 22 bases. miRNAs function as
the guide sequence of the RNA-induced silencing complex (RISC), a post-transcriptional
regulatory body that targets and degrades coding sequences, thereby preventing the translation of
the protein. By controlling regulatory complexes such as RISC, in addition to altering cellular
response through viral proteins, HPV may be able to prolong its own replicative cycle, while also
making more subtle changes that can assist in the development of tumor growth. HPV does not
encode any of its own miRNAs, but has been shown to induce changes in host miRNA
expression level. Examples include miR-9-5p, which has been reported as upregulated in
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HPV(+) cervical and oropharyngeal cancers, miR-145-5p, which has been shown as
downregulated by HPV33, and miR-23b, which has been shown to be downregulated by HPV16
(5-8). The subsequent cellular responses can include increased motility, as associated with miR9-5p targets, genome amplification through the suppression of miR-145-5p, and increased
expression of the oncogene cMet, through miR-23b downregulation (5,7,8).
Interestingly, HPV has also been shown to be a powerful prognostic marker for improved
cancer survival. In this context, a number of studies have also examined miRNA-mediated
responses, and the potential mechanisms by which miRNAs can function as biomarkers for
survival. The former has been demonstrated in the development of miRNA-profile derived
survival signatures in cervical and oropharyngeal cancers, which may be used in the clinical
setting to aid in determining course of treatment (9-13). Due to the varying survival rates based
on HPV infection status, a common focus of these studies, especially in oropharyngeal cancers,
is to demonstrate that these miRNA-based signatures can maintain significance in both HPV(+)
and HPV(-) cohorts. However, the mechanisms by which HPV is capable of both inducing tumor
formation as well as improving patient survival after diagnosis are unclear.
With this in mind, we have aimed to identify distinct miRNA-mediated pathways that
indicate either HPV-induced tumor growth or HPV-related tumor survival. Using 79
oropharyngeal cancer samples and 301 cervical cancer samples obtained from The Cancer
Genome Atlas, we have identified HPV-dysregulated microRNAs and coding transcripts.
Further, we have identified potential miRNA targets, and by implementing pathway analysis, we
have also identified a number of distinct mechanisms as potentially controlled through the
miRNA regulatory mechanism. In summary, we have identified miRNA-controlled mechanisms
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that supplement HPV-induced oncogenesis, as well as revealed potential genomic and
miRNomic responses that may result in improved tumor survival.

4.3

Materials and Methods

Data Retrieval
A total of 81 oropharyngeal cancer patients and 303 cervical cancer patients were
identified in The Cancer Genome Atlas (Table 4.1). Through the Genomic Data Commons Data
Portal (portal.gdc.cancer.gov), raw RNA-seq and miRNA-seq data were obtained for 79 patients
in the oropharyngeal cancer group, and 301 cervical cancer patients (14). All gene sequences
were downloaded from the UCSC Genome Browser (15). Index files mapping transcript
accessions to NCBI Gene IDs were downloaded from the NCBI ftp site (16). Complete HPV
genomes were downloaded from the Papillomavirus Episteme (17). All mature miRNA
sequences were downloaded from miRBase (18).

TCGA Sequence Analysis
Sequence alignment was performed using the Bowtie program (19). Raw miRNA-Seq
reads were aligned to the human miRNome. The read counts were then normalized to reads per
million reads mapped per sample and set to a floor value of 1 for lowly expressed miRNAs
before being log2 normalized. Raw RNA-seq reads were aligned sequentially to human RefSeq
annotated sequences, the human reference genome, and the virome. The read counts were
normalized to reads per kilobase per million mapped reds (RPKM), then to the 200th gene before
being set to a floor of 5 normalized reads for lowly expressed transcripts.
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Statistical Analysis for miRNA Correlation to HPV Status
miRNA and coding transcript expression levels were examined for significance in
Table 4.1: Patient characteristics of the HPV cancer cohorts
All Cervical
Cancer

Cervical
Squamous Cell
Carcinoma
254
252
48.8+14.1
471

Oropharyngeal
Cervical AdenoSquamous Cell
type Carcinoma
Carcinoma
50
81
49
79
45.3+12.3
55.9+9.3
241
637

307
Total patient count
301
Patients included
48.2+13.9
Age at diagnosis + SD
Median follow up time (days) 350
Sex
Female
301
252
49
11
Male
0
0
0
68
Race
White
206
169
37
73
Black or African American 30
28
2
6
Other
29
24
5
0
Unreported
36
31
5
0
281 (93.4%)
240 (95.2%)
41 (83.6%)
52 (65.8%)
HPV (+)
Smokinga
Nonsmoker
142
114
28
23
Long-term former smoker 9
8
1
8
Other former smoker
44
36
8
25
Current smoker
63
54
9
22
Unreported
43
40
3
1
T classification
TX
17
15
2
4
Tis
1
1
0
0
T1
137
110
27
13
T2
71
58
13
31
T3
20
18
2
19
T4
10
9
1
4
Unreported
45
41
4
0
N classification
NX
66
56
10
3
N0
130
104
26
21
N1
60
51
9
8
N2
0
0
0
43
N3
0
0
0
4
Unreported
45
41
4
0
Stage
I
159
125
34
5
II
76
69
7
10
III
38
35
3
13
IV
21
16
5
49
Unreported
7
7
0
2
72
61
11
22
Deceased in study
a
Smoking was defined as no history of smoking, a former smoker of >= 15 years, other former smoker of <15
years, or a current smoker.

111

relation to HPV status in individual tumor types. Coding transcripts were evaluated using the
Student’s t-test. miRNA expression levels were evaluated using a permutation test, also called
label shuffling. Specifically, HPV status was randomly assigned to samples in the cohort while
maintaining the same proportion of HPV positive patients. Expression fold change for the
miRNA was calculated for the shuffled cohort. After one million iterations of this permutation,
the true expression fold change was ranked in comparison to the randomly determined fold
changes; its position in relation to the shuffled set constituted its significance.

Target and Pathway Analysis
Likely miRNA-target interactions were initially identified using the MirTarget (version 3)
algorithm, the results of which were obtained from miRDB.org (20,21). Additional filters were
used to confirm that the results were properly associated, i.e. that miRNA expression was
negatively correlated with target expression in the given cohort.
Pathway analysis was conducted on significantly dysregulated targets using the
PANTHER algorithm (22). Raw p-values calculated using the binomial test were used to identify
significantly overrepresented or underrepresented pathways associated with the Gene Ontology
Consortium definitions (23,24).

4.4 Results
Dysregulation of miRNAs in Cervical and Oropharyngeal Cancers in Response to HPV Infection
Within oropharyngeal cancers, 440 miRNAs were identified as being expressed, i.e.
having a log2 mean expression greater than 0.5 across all samples. Of these 440 expressed
miRNAs, permutation analysis using a 2-tailed curve identified 207 as significantly
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Table 4.2: HPV-dysregulated miRNAs in OPSCC
hsa-miR-20b-5p

raw pvalue
0

0

log2 fold
change
3.517471

hsa-miR-30e-5p

raw pvalue
1E-06

0.00044

log2 fold
change
0.829569

hsa-miR-9-5p

0

0

3.28475

hsa-miR-625-5p

9E-06

0.00396

0.816012

hsa-miR-363-3p

0

0

2.995527

hsa-miR-1295a

4E-06

0.00176

0.800879

hsa-miR-106a-5p

0

0

2.31328

hsa-miR-30e-3p

0

0

0.751577

hsa-miR-20b-3p

0

0

2.282462

hsa-miR-7-1-3p

1.4E-05

0.00616

0.725956

hsa-miR-9-3p

0

0

2.0645

hsa-miR-548b-3p

2.1E-05

0.00924

0.698775

hsa-miR-99a-5p

0

0

1.955681

hsa-miR-25-3p

2E-06

0.00088

0.688253

hsa-miR-125b-2-3p

1.6E-05

0.00704

1.754344

hsa-miR-107

2.5E-05

0.011

0.634541

hsa-miR-150-3p

1.1E-05

0.00484

1.514754

hsa-miR-34a-5p

3.8E-05

0.01672

0.627293

hsa-let-7c-5p

1.1E-05

0.00484

1.457579

hsa-miR-2277-5p

6E-06

0.00264

0.607582

hsa-miR-378c

0

0

1.415099

hsa-miR-3610

2.8E-05

0.01232

0.593877

hsa-miR-1266-5p

2.4E-05

0.01056

1.302272

hsa-miR-22-3p

0.000021

0.00924

-0.55274

hsa-miR-148a-5p

3E-06

0.00132

1.214824

hsa-miR-22-5p

0.000015

0.0066

-0.7918

hsa-miR-29c-3p

2.3E-05

0.01012

1.214248

hsa-miR-365a-3p

0.000016

0.00704

-0.87431

hsa-miR-598-3p

4.2E-05

0.01848

1.164478

hsa-miR-655-3p

0.00002

0.0088

-0.90531

hsa-miR-378a-3p

1.2E-05

0.00528

1.158094

hsa-miR-455-5p

0.000013

0.00572

-0.96418

hsa-miR-378a-5p

4E-06

0.00176

1.057344

hsa-miR-193b-5p

0.000016

0.00704

-0.98032

hsa-miR-15b-5p

0

0

1.049673

hsa-miR-199b-5p

0.000023

0.01012

-1.04124

hsa-miR-148a-3p

6E-06

0.00264

1.049506

hsa-miR-493-3p

0.000045

0.0198

-1.1074

hsa-miR-101-3p

0

0

1.036463

hsa-miR-369-3p

0.000024

0.01056

-1.13486

hsa-miR-16-2-3p

2E-05

0.0088

1.018546

hsa-miR-214-3p

0.00002

0.0088

-1.13489

hsa-miR-582-3p

2E-06

0.00088

1.007475

hsa-miR-2355-5p

0.000001

0.00044

-1.17311

hsa-miR-3917

0

0

0.993058

hsa-miR-376c-3p

0.000009

0.00396

-1.1785

hsa-miR-15b-3p

2E-06

0.00088

0.960788

hsa-miR-493-5p

0.000049

0.02156

-1.18468

hsa-miR-200b-3p

1E-06

0.00044

0.936816

hsa-miR-214-5p

0.000006

0.00264

-1.23375

hsa-miR-30d-3p

0

0

0.935208

hsa-miR-299-5p

0.000001

0.00044

-1.2757

hsa-miR-200b-5p

1E-05

0.0044

0.934769

hsa-miR-432-5p

0.000013

0.00572

-1.32626

hsa-miR-200a-5p

1.7E-05

0.00748

0.923817

hsa-miR-193b-3p

0

0

-1.43176

hsa-miR-625-3p

1E-06

0.00044

0.886313

hsa-miR-2355-3p

0.000001

0.00044

-1.44537

hsa-miR-30d-5p

0

0

0.852316

hsa-miR-584-5p

0

0

-1.6966

hsa-miR-16-5p

3E-06

0.00132

0.833649

hsa-miR-31-3p

0.000026

0.01144

-2.02521

miRNA

FWER

miRNA

FWER

dysregulated; 62 miRNAs maintained significance after Bonferroni multiple testing correction
(Table 4.2). Similar numbers were observed in the cervical cancer cohort. Using the entire
patient cohort across all HPV types, 426 miRNAs were defined as expressed. By raw p-value,
191 miRNAs were significantly dysregulated in response to HPV, 44 of which were maintained
after Bonferroni correction (11 upregulated, 33 downregulated) (Table 4.3).
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Table 4.3: HPV-dysregulated miRNAs in CESC
hsa-miR-944

raw pvalue
0

0

log2 fold
change
3.397764

hsa-miR-425-3p

raw pvalue
0

0

log2 fold
change
-1.02183

hsa-miR-205-5p

3E-06

0.001278

3.127832

hsa-miR-181c-3p

0.000004

0.001704

-1.03397

hsa-miR-31-5p

0

0

2.597114

hsa-miR-539-5p

0.00004

0.01704

-1.05188

hsa-miR-31-3p

0

0

2.196549

hsa-miR-130b-5p

0.000002

0.000852

-1.06675

hsa-miR-224-5p

3.7E-05

0.015762

1.569408

hsa-miR-96-5p

0.00001

0.00426

-1.10145

hsa-miR-205-3p

8E-06

0.003408

1.49973

hsa-miR-369-3p

0.000034

0.014484

-1.10919

hsa-miR-224-3p

3.1E-05

0.013206

1.063936

hsa-miR-744-3p

0.000035

0.01491

-1.11066

hsa-miR-221-3p

5.8E-05

0.024708

1.053583

hsa-miR-1468-5p

0

0

-1.11834

hsa-miR-21-3p

6E-06

0.002556

0.928698

hsa-miR-191-5p

0

0

-1.12185

hsa-let-7b-5p

1.8E-05

0.007668

0.677123

hsa-miR-425-5p

0.000001

0.000426

-1.12377

hsa-miR-21-5p

4.6E-05

0.019596

0.478553

hsa-miR-501-3p

0.000005

0.00213

-1.15102

hsa-miR-151a-5p

0.000015

0.00639

-0.61152

hsa-miR-323b-3p

0.000007

0.002982

-1.16143

hsa-miR-148b-5p

0.000022

0.009372

-0.6658

hsa-miR-495-3p

0.000025

0.01065

-1.16932

hsa-miR-324-5p

0.000036

0.015336

-0.77744

hsa-miR-183-5p

0.00001

0.00426

-1.18963

hsa-miR-744-5p

0.000039

0.016614

-0.78916

hsa-miR-432-5p

0.000029

0.012354

-1.21449

hsa-miR-93-3p

0.000011

0.004686

-0.79362

hsa-miR-483-3p

0.000054

0.023004

-1.2179

hsa-miR-340-3p

0.000001

0.000426

-0.80925

hsa-miR-323a-3p

0.000006

0.002556

-1.33359

hsa-miR-324-3p

0.000041

0.017466

-0.81764

hsa-miR-191-3p

0

0

-1.36666

hsa-miR-887-3p

0.000056

0.023856

-0.82948

hsa-miR-431-3p

0.000002

0.000852

-1.57704

hsa-miR-874-3p

0.000039

0.016614

-0.90159

hsa-miR-3200-3p

0

0

-1.84847

hsa-miR-103a-2-5p

0.000022

0.009372

-0.94129

hsa-miR-767-5p

0.000036

0.015336

-2.47921

hsa-miR-500a-3p

0.000008

0.003408

-0.94769

hsa-miR-105-5p

0.000026

0.011076

-2.73646

miRNA

FWER

miRNA

FWER

Of the two Bonferroni corrected sets, there are only three miRNAs that are significant in
both oropharyngeal and cervical cancers: miR-31-3p, miR-369-3p, and miR-432-5p. The most
notable of the three overlapping miRNAs is miR-31-3p, which was identified as upregulated by
HPV in cervical cancer but downregulated by HPV in oropharyngeal cancer. The remaining two
miRNAs in this subset were both downregulated by HPV.

Pathway Analysis of Dysregulated miRNA Targets Indicates miRNA Effects Supplement Basal
HPV Activity
Identification of distinct microRNA-target interactions was performed independently
through the significantly dysregulated miRNAs and the significantly dysregulated gene
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TCGA: RNASeq
Sequence alignment
HPV Status
Statistical analysis
Dysregulated
miRNAs

Dysregulated
genes
Target analysis

Potential gene
targets

Potential miRNA
actors

Figure 4.1: Mechanism for identifying miRNA-target interactions in cancers. After determining
HPV status through alignment to the virome, miRDB was used to identify targets of dysregulated
miRNAs were identified through miRDB (left fork) and potential miRNA regulators of dysregulated
transcripts (right fork).

transcripts (Figure 4.1). In the first method, targets of miRNAs significantly associated to HPV
status were determined to be affected if the target fulfilled the following criteria: 1) the target is
identified in miRDB as associated with the miRNA with a score greater than 50; 2) the target has
an average expression greater than 6 RPKM; and 3) the transcript expression is negatively
correlated with miRNA expression. In this technique, the significance of the target expression in
relation to HPV status was not taken into account. A total of 2607 potential targets were
identified as being targeted by dysregulated miRNAs in oropharyngeal cancer: 2333 in the
HPV(+) cohort and 274 in the HPV(-) cohort. In the cervical cancer cohort, a total of 2638
potential miRNA targets were identified: 2051 in the HPV(+) cohort and 587 in the HPV(-)
group. The inverse relationship was also explored; specifically, the significance of gene
transcripts in response to HPV as the experimental factor was determined, and potential miRNA
regulators were identified using the same criteria including miRDB score, expression as defined
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previously, and negative correlation between miRNA and target. In OPSCC, this yielded 500
significant transcripts in the HPV(+)cohort and 354 transcripts in the HPV(-) cohort; in CESC,
this yielded 1583 transcripts in the HPV(+) group and 384 in the HPV(-) group.
The targets of the potential miRNA interactions were then analyzed using the PANTHER
database, available at pantherdb.org (22). PANTHER implements the Gene Ontology (GO)
database to determine if certain gene sets, such as those defined by GO as members in the same
biological process, are overrepresented in a submitted set of genes. Significance is determined
with the binomial test. When using significant miRNAs as the initial feature, a total of 55
biological processes were identified as significantly overrepresented by upregulated genes in the
HPV(+) oropharyngeal cancer dataset, while 53 processes were significantly underrepresented
(Supplementary Table 4.1). In the HPV(+) cervical cancer datasets, 43 biological processes were
overrepresented and 23 processes underrepresented (Supplementary Table 4.2). Among the
HPV(-) datasets, 24 biological processes were significantly overrepresented by potential miRNA
targets among oropharyngeal cancers, and 10 were underrepresented (Supplementary Table 4.3).
The HPV(-) cervical cancer set, although limited in scope, showed 22 overrepresented biological
processes and 31 underrepresented processes (Supplementary Table 4.4). Notable processes that
were upregulated in HPV(+) tumors of both species include DNA processes of replication,
recombination and repair, metabolic processes, cellular component organization, mitosis, and
stress response; while downregulated pathways include cell recognition, complement activation,
and GPCR signaling pathways. Processes upregulated in both HPV(-) cancer types include
cellular component organization and rRNA metabolic processes. The only process
downregulated in both HPV(-) tumor types was immune response.
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Using dysregulated gene transcripts as the initial focus yielded similar results. After
filtering by using potential miRNA dysregulation and interaction, 28 pathways were
overrepresented in HPV(+) oropharyngeal tumors and 9 pathways were downregulated
(Supplementary Table 4.5), while 45 pathways were upregulated in HPV(+) cervical cancer and
23 were downregulated (Supplementary Table 4.6). In HPV(-) oropharyngeal tumors, 37
biological processes were overrepresented and 27 underrepresented (Supplementary Table 4.7).
Comparatively in HPV(-) cervical cancers, 9 processes were upregulated and 23 were
underrepresented (Supplementary Table 4.8). The HPV(+) cohorts shared an overrepresentation
of cellular defense response, immune responses, signaling cascades, and metabolic processes,
while also demonstrating an underrepresentation of translation and defense response to
bacterium. In the HPV(-) cohort, both cancer types showed an overrepresentation of cellular
component biogenesis, metabolic processes, organelle organization, and translation, along with
an underrepresentation of general biological regulation, immune response, and both intercellular
and intracellular communication. Similar results were observed when comparing the pathway
analyses generated with the two different methods of identifying potential targets, suggesting
that the observed biological processes may be supplemented, rather than exclusively moderated,
by miRNA dysregulation.

Individual miRNA-Target Interactions are Conserved in HPV-Related Cancers
By evaluating statistical significance of downregulated targets, in addition to statistical
significance of miRNAs, a small subset of potential miRNA-target interactions were identified to
be conserved between the two HPV-related cancer types (Table 12). These interactions were
identified using significance for both miRNA expression and target expression (p<0.05), in
addition to the same criteria as described previously: miRDB score, target expression, and
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Table 4.4: miRNA-Target Interactions Conserved Between Cervical and Oropharyngeal Cancers in
Response to HPV Status
Targets of miRNAs Downregulated in HPV(+) Tumors
hsa-miR-105-5p
hsa-miR-105-5p
hsa-miR-105-5p
hsa-miR-105-5p
hsa-miR-105-5p
hsa-miR-136-5p
hsa-miR-136-5p
hsa-miR-154-3p
hsa-miR-154-5p
hsa-miR-154-5p
hsa-miR-181a-2-3p
hsa-miR-181a-2-3p
hsa-miR-181a-2-3p
hsa-miR-181a-2-3p
hsa-miR-181b-5p
hsa-miR-181b-5p
hsa-miR-181b-5p
hsa-miR-181b-5p
hsa-miR-181b-5p
hsa-miR-181b-5p
hsa-miR-3127-5p
hsa-miR-323a-3p
hsa-miR-323a-3p
hsa-miR-323a-3p
hsa-miR-337-3p
hsa-miR-337-3p
hsa-miR-337-3p
hsa-miR-369-3p
hsa-miR-369-3p
hsa-miR-369-3p
hsa-miR-370-3p
hsa-miR-370-3p
hsa-miR-370-3p
hsa-miR-370-3p
hsa-miR-370-3p
hsa-miR-370-3p
hsa-miR-382-5p
hsa-miR-382-5p
hsa-miR-409-3p
hsa-miR-409-3p
hsa-miR-410-3p
hsa-miR-410-3p
hsa-miR-432-5p
hsa-miR-432-5p
hsa-miR-450b-5p
hsa-miR-450b-5p
hsa-miR-483-3p

FCER1A
MECP2
TAF9B
SNIP1
MED14
BTN3A2
IFNGR1
KDM6A
PCNA
CLOCK
TMEM173
IL13RA1
LY75
MED14
COL16A1
KLF6
GANC
TAF9B
ZFP36L1
SNN
CLOCK
PIGK
STAT3
KLF11
CCDC50
IL13RA1
STAT3
PIGK
DPYD
UGCG
MESDC2
GJB3
PMAIP1
DCLRE1B
STAT3
N4BP2L1
FAM120C
PRPS2
DCLRE1B
MED14
KLF6
HS3ST1
MECP2
N4BP2L1
ENOX2
ADRB2
ICAM1

hsa-miR-483-3p
hsa-miR-485-3p
hsa-miR-485-3p
hsa-miR-485-3p
hsa-miR-485-3p
hsa-miR-493-3p
hsa-miR-493-5p
hsa-miR-493-5p
hsa-miR-493-5p
hsa-miR-493-5p
hsa-miR-493-5p
hsa-miR-495-3p
hsa-miR-495-3p
hsa-miR-495-3p
hsa-miR-495-3p
hsa-miR-495-3p
hsa-miR-495-3p
hsa-miR-495-3p
hsa-miR-495-3p
hsa-miR-514a-3p
hsa-miR-514a-3p
hsa-miR-539-5p
hsa-miR-539-5p
hsa-miR-539-5p
hsa-miR-539-5p
hsa-miR-539-5p
hsa-miR-539-5p
hsa-miR-539-5p
hsa-miR-654-3p
hsa-miR-654-3p
hsa-miR-654-3p
hsa-miR-654-3p
hsa-miR-654-5p
hsa-miR-655-3p
hsa-miR-655-3p
hsa-miR-655-3p
hsa-miR-655-3p
hsa-miR-675-3p
hsa-miR-675-3p
hsa-miR-675-3p
hsa-miR-758-3p
hsa-miR-758-3p
hsa-miR-758-3p
hsa-miR-767-5p
hsa-miR-767-5p
hsa-miR-767-5p
hsa-miR-767-5p

MECP2
PIGK
KLF6
MAPKBP1
MAT2B
KLF6
IRF2
LAMP2
KDM6A
SNN
CLOCK
IRF2
DCLRE1B
STAT3
UGCG
SNIP1
CARD6
RUNX3
CLOCK
KLF6
SNIP1
CCDC50
FAM120C
CPPED1
DCLRE1B
ZFP36L1
KDM6A
CLOCK
CENPI
FUNDC2
MED14
LITAF
EDARADD
PIGK
UBD
DPYD
MOB3B
ATG4A
FAM120C
MED14
PLP2
KDM6A
MOB3B
KLF6
CCDC50
NASP
N4BP2L1

Targets of miRNAs Upregulated in
HPV(+) Tumors
hsa-miR-101-3p
XPO5
hsa-miR-101-3p
PMPCB
hsa-miR-142-5p
CNOT11
hsa-miR-16-1-3p
NLN
hsa-miR-205-3p
CIAO1
hsa-miR-29c-3p
GCSH

directional correlation. In doing so, 96 target interactions resulting from HPV-downregulated
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miRNAs were identified as conserved between OPSCC and CESC, spanning 30 unique miRNAs
and 52 unique targets. A number of gene transcripts were targeted by multiple miRNAs in this
set; considering that the respective miRNAs are downregulated, these particular transcripts were
upregulated. Of note are the tumor suppressor KLF6, the circadian rhythm gene CLOCK, and
STAT3. Interestingly, increased activation of STAT3, a vital component of the JAK/STAT
signaling pathway, promotes cancer growth and angiogenesis, while overexpression of CLOCK
and KLF6 are both associated with tumor survival and reduction in tumor size (25-28). Only 6
total miRNA-target interactions were conserved by HPV-upregulated miRNAs; none of the
targets of the identified interactions are noted in the literature for their involvement in cancer.

4.5

Discussion
Human papillomavirus infection causes approximately 95% of all cervical cancers, and

may be responsible for up to 75% of new oropharyngeal cancer diagnoses (29,30). The role of
HPV in tumor formation has been well-characterized, along with its prognostic significance after
diagnosis (31,32). However, the mechanisms that result in this unusual dichotomy are not well
characterized and may be controlled through some more subtle regulatory mechanisms, such as
the RNAi mechanism in which miRNAs are involved.

HPV

miRNA

Gene
Targets

Tumor formation/
Tumor survival

expression
Figure 4.2: A diagram of potential miRNA-mediated dysregulation in response to HPV. HPV
infection can induce changes in miRNA expression levels, which result in the opposite effect of the
potential gene transcript targets. Through the miRNA regulatory network, mechanisms of tumor
formation may be supplemented, and additional mechanisms of tumor survival may be characterized.
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The dysregulation of miRNA expression in response to HPV infection can result in
downstream effects in the transcriptome prior to translation (Figure 2). Therefore, we aimed to
identify both significantly dysregulated miRNA regulators and potential gene targets between
HPV(+) and HPV(-) tumors. Contemporary pathway analysis, including PANTHER and Gene
Set Enrichment Analysis, focuses primarily on coding transcripts and occasionally long noncoding RNAs (22,33). Therefore, we employed the PANTHER database to analyze the gene
transcripts that we identified as potential targets of dysregulated miRNAs; to confirm our results,
we also performed the analysis based on dysregulated transcripts, and performed target analysis
to identify potential miRNA actors. Many of the biological processes that were determined to be
significantly selected through both techniques could be inferred as associated with HPV-induced
oncogenesis. For example, overrepresented processes in HPV(+) tumors included processes that
are conceivably associated with cell growth and replication, such as mitosis, cellular component
organization, metabolism, and cell cycle, while underrepresented processes included immune
responses such as cell recognition. The underrepresented immune response in HPV(+) tumors
suggest immune evasion, which has been indicated in the literature as one of the roles of the E2
protein (34). The HPV(-) tumors also show overrepresentation of the processes that can be
inferred as relevant in oncogenesis, as well as a lack of immune response, which in this context
may simply be unnecessary; however, HPV(-) tumors also indicate that biological processes
associated with cell adhesion and cell communication are significantly underrepresented; this
may account for poorer prognosis in the sense of encouraging metastasis and unchecked cell
replication and growth. One of the primary weaknesses of PANTHER analysis is its inability to
account for expression level, especially when compared to GSEA; however, PANTHER is more
effective than GSEA when examining smaller gene sets.
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Individual miRNA-target interactions were not ignored in this analysis; although a toplevel pathway analysis can provide guidance as to how miRNAs may operate in response to HPV
infection, individual miRNA-target interactions can also indicate potential therapeutic targets.
This type of analysis has been proposed previously using HPV-infected NIKS cells (35), but to
the best of our knowledge, this study is the first to examine such interactions using transcriptome
and miRNome data from patient tissue samples. CLOCK, KLF6, and STAT3 have already been
highlighted. Other targets that were overexpressed in HPV(+) tumors and targeted by
downregulated miRNAs include the pro-survival gene CCDC50, the tumor suppressor KDM6A,
and the oncogene SNIP1 (36-38). This combination of pro-survival and tumor suppressor genes
with oncogenes among targets of dysregulated miRNAs indicate possible divergent mechanisms
for tumor formation and later survival; these particular interactions are strong candidates for
direct analysis through cellular and in-house experiments.
Adenocarcinomas and adenosquamous cell carcinomas of the cervix (cervical adeno-type
carcinomas) are both histologically and genetically distinct from cervical squamous cell
carcinomas (39,40). Additionally, there have been reports that members of the
alphapapillomavirus 9 species enriched in adenosquamous cell carcinomas and adenocarcinomas
of the cervix, in comparison to squamous cell carcinomas of the cervix (41). In conducting our
HPV sequencing analysis, we determined that these previous findings are consistent within the
cervical cancer cohort from TCGA (Table 4.5). The distribution of HPV types in cervical adenotype carcinomas significantly favors members of the Alphapapillomavirus type 9 species, as well
as HPV(-) tumors, at the expense of the more common Alphapapillomavirus type 7 species (χ2
p= 0.027). This observation is not observed in cervical squamous cell carcinomas (χ2 p= 0.71).
Interestingly, HPV(+) OPSCCs from TCGA are all infected by members of the
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Table 4 5: HPV types in cervical and oropharyngeal cancers, separated by tumor source site
HPV
species

HPV type

All Cervical
Cancer

Alpha9

HPV16

163

Cervical
Squamous Cell
Carcinoma
136

27

Oropharyngeal
Squamous Cell
Carcinoma
45

HPV31

7

7

0

0

HPV33
HPV35

9

9

0

4

6

6

0

3

HPV52

8

8

0

0

HPV58

7

7

0

0

Total

200

173

27

52

HPV18

37

27

10

0

HPV39

6

6

0

0

HPV45

22

19

3

0

HPV59

3

3

0

0

HPV68

2

2

0

0

Total

70

57

13

0

HPV26

1

1

0

0

HPV30

1

1

0

0

HPV51

1

1

0

0

HPV56

1

1

0

0

HPV69

1

1

0

0

HPV70

2

2

0

0

HPV73

2

2

0

0

Total

9

9

0

0

Multiple

2

1

1

0

HPV(-)

20

12

8

27

Alpha7

Other

Cervical Adenotype Carcinoma

Alphapapillomavirus 9 species; considering that such tumors can cluster together with cervical
squamous tumors, this preferential infectivity is not entirely unexpected.
Additional analysis can also be performed on the basis of HPV species. It has been shown
that miR-9-5p is upregulated to a greater extent by HPV16, a member of the alphapapillomavirus
9 species, than HPV18, a member of the higher risk alphapapillomavirus 7 species (5).
However, the effect of HPV type on the dysregulation of the miRNome as a whole is unclear,
especially considering that there is a preference for infection of adeno-type carcinomas by the
higher risk species (41-43). This correlation begs the question of whether the higher risk of
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adeno-type cancers results from the higher risk papillomaviruses, and the role of regulatory
miRNAs in promoting patient survival.
Through these analyses, we have laid the foundation for examining miRNA-controlled
mechanisms for supplementing HPV-derived tumor formation, as well as HPV-related tumor
survival. By modulating and altering the host miRNome, HPV is able to prolong cell survival
and replication, as well as activate various pro-survival and tumor suppressors after tumor
formation. We have demonstrated some of the miRNA-based mechanisms that may be induced
by HPV, and believe that a continued focus on how regulatory systems such as RNAi will be
able to elucidate the unusual behavior of HPV that causes infection to be both oncogenic and
pro-survival.
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4.7 Supplementary Tables
Supplementary Table 4.1: Significant biological processes in HPV(+) OPSCC, through initial
identification of significantly dysregulated miRNAs and subsequent targets
Overrepresented Processes
Process Name (GO Number)

Underrepresented Processes
P-value

Process Name (GO Number)

P-value

apoptotic process (GO:0006915)

2.15E-02

system process (GO:0003008)

1.41E-20

biosynthetic process (GO:0009058)
carbohydrate metabolic process
(GO:0005975)

2.03E-04

angiogenesis (GO:0001525)

8.19E-06

3.86E-03

anion transport (GO:0006820)

5.56E-04

catabolic process (GO:0009056)

5.83E-10

B cell mediated immunity (GO:0019724)

1.09E-03

cell cycle (GO:0007049)

8.91E-10

behavior (GO:0007610)

2.50E-02

cell death (GO:0008219)
cellular amino acid metabolic process
(GO:0006520)
cellular component organization
(GO:0016043)
cellular component organization or
biogenesis (GO:0071840)

3.80E-02

biological adhesion (GO:0022610)

2.20E-03

2.44E-02

biological regulation (GO:0065007)

8.28E-05

6.24E-07

blood circulation (GO:0008015)

4.73E-06

4.68E-06

cation transport (GO:0006812)

4.91E-02

cellular process (GO:0009987)
cellular protein modification process
(GO:0006464)

1.87E-04

cell adhesion (GO:0007155)

2.20E-03

4.44E-04

cell communication (GO:0007154)

1.93E-03

chromatin organization (GO:0006325)

1.38E-09

cell differentiation (GO:0030154)

1.55E-03

chromosome segregation (GO:0007059)

2.15E-03

3.66E-02

cytoskeleton organization (GO:0007010)

1.22E-04

cell recognition (GO:0008037)
cell surface receptor signaling pathway
(GO:0007166)

death (GO:0016265)

3.80E-02

cell-cell adhesion (GO:0016337)

1.61E-02

DNA metabolic process (GO:0006259)

4.20E-13

cell-cell signaling (GO:0007267)

1.84E-05

DNA recombination (GO:0006310)

3.39E-04

cell-matrix adhesion (GO:0007160)

4.52E-03

DNA repair (GO:0006281)

3.96E-08

9.89E-03

DNA replication (GO:0006260)

1.44E-07

complement activation (GO:0006956)
defense response to bacterium
(GO:0042742)

fatty acid beta-oxidation (GO:0006635)

2.06E-03

1.77E-04

induction of apoptosis (GO:0006917)

3.83E-02

developmental process (GO:0032502)
digestive tract mesoderm development
(GO:0007502)

lysosomal transport (GO:0007041)

1.08E-02

ectoderm development (GO:0007398)

1.28E-05

meiosis (GO:0007126)

2.76E-04

female gamete generation (GO:0007292)

3.51E-02

metabolic process (GO:0008152)

5.24E-24

4.47E-02

mitosis (GO:0007067)

2.35E-05

fertilization (GO:0009566)
G-protein coupled receptor signaling
pathway (GO:0007186)

mRNA processing (GO:0006397)
mRNA splicing, via spliceosome
(GO:0000398)
nitric oxide biosynthetic process
(GO:0006809)
nitrogen compound metabolic process
(GO:0006807)

3.86E-16

heart development (GO:0007507)

1.02E-03

5.69E-13

immune response (GO:0006955)

2.17E-04

4.32E-02

immune system process (GO:0002376)

6.70E-03

2.01E-12

ion transport (GO:0006811)

4.44E-05

nuclear transport (GO:0051169)
nucleobase-containing compound metabolic
process (GO:0006139)

1.14E-02

macrophage activation (GO:0042116)

3.31E-02

1.63E-25

mesoderm development (GO:0007498)

5.97E-04
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3.98E-08

1.80E-03

2.72E-02

2.41E-07

nucleobase-containing compound transport
(GO:0015931)

3.03E-02

multicellular organismal process
(GO:0032501)

4.96E-19

organelle organization (GO:0006996)
phosphate-containing compound metabolic
process (GO:0006796)
phospholipid metabolic process
(GO:0006644)

1.06E-14

muscle contraction (GO:0006936)

8.34E-06

4.39E-10

muscle organ development (GO:0007517)

9.76E-04

5.58E-03

natural killer cell activation (GO:0030101)

1.56E-02

primary metabolic process (GO:0044238)

1.88E-19

nervous system development (GO:0007399)

8.25E-05

protein acetylation (GO:0006473)

1.95E-03

neurological system process (GO:0050877)

5.40E-15

protein localization (GO:0008104)

2.36E-03

4.41E-02

protein methylation (GO:0006479)

4.92E-02

protein targeting (GO:0006605)
pyrimidine nucleobase metabolic process
(GO:0006206)

5.86E-03

pattern specification process (GO:0007389)
regulation of biological process
(GO:0050789)
regulation of vasoconstriction
(GO:0019229)

7.55E-03

response to biotic stimulus (GO:0009607)

1.41E-02

regulation of cell cycle (GO:0051726)
regulation of nucleobase-containing
compound metabolic process (GO:0019219)
regulation of phosphate metabolic process
(GO:0019220)
regulation of transcription from RNA
polymerase II promoter (GO:0006357)

1.27E-05

response to stimulus (GO:0050896)

5.17E-07

2.45E-05

2.19E-15

2.65E-02

sensory perception (GO:0007600)
sensory perception of chemical stimulus
(GO:0007606)

6.10E-05

sensory perception of smell (GO:0007608)

2.22E-14

regulation of translation (GO:0006417)

1.17E-02

sensory perception of sound (GO:0007605)

2.74E-02

response to stress (GO:0006950)

4.78E-02

sensory perception of taste (GO:0050909)

3.95E-02

RNA catabolic process (GO:0006401)

2.29E-03

3.60E-03

RNA localization (GO:0006403)

1.75E-02

signal transduction (GO:0007165)
single-multicellular organism process
(GO:0044707)

RNA metabolic process (GO:0016070)
RNA splicing, via transesterification
reactions (GO:0000375)
transcription from RNA polymerase II
promoter (GO:0006366)
transcription initiation from RNA
polymerase II promoter (GO:0006367)
transcription, DNA-dependent
(GO:0006351)
tRNA aminoacylation for protein translation
(GO:0006418)

2.07E-12

skeletal system development (GO:0001501)

3.97E-04

6.02E-11

steroid metabolic process (GO:0008202)

2.37E-02

1.73E-06

synaptic transmission (GO:0007268)

5.54E-04

1.01E-02

system development (GO:0048731)

4.03E-07

4.86E-04
1.72E-03
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8.62E-05
1.75E-02

2.12E-19

1.58E-18

Supplementary Table 4.2: Significant biological processes in HPV(+) CESC, through initial
identification of significantly dysregulated miRNAs and subsequent targets
Overrepresented Processes
Process Name (GO Number)
7-methylguanosine mRNA capping
(GO:0006370)
antigen processing and presentation
(GO:0019882)

Underrepresented Processes
P-value

Process Name (GO Number)

P-value

3.15E-02

cell recognition (GO:0008037)

5.00E-03

1.27E-02

complement activation (GO:0006956)
defense response to bacterium
(GO:0042742)

1.49E-02

gamete generation (GO:0007276)
G-protein coupled receptor signaling
pathway (GO:0007186)

4.17E-02

1.30E-02

4.98E-04

mitochondrion organization (GO:0007005)
multicellular organismal process
(GO:0032501)

3.29E-03

muscle organ development (GO:0007517)

3.49E-02

7.51E-04

neurological system process (GO:0050877)

1.27E-06

biological adhesion (GO:0022610)

3.06E-03

catabolic process (GO:0009056)

1.80E-02

cell adhesion (GO:0007155)

3.06E-03

cell cycle (GO:0007049)
cellular component morphogenesis
(GO:0032989)
cellular component movement
(GO:0006928)
cellular component organization
(GO:0016043)
cellular component organization or
biogenesis (GO:0071840)

1.23E-05

9.96E-03

oxidative phosphorylation (GO:0006119)

1.11E-02

cellular defense response (GO:0006968)

2.86E-02

phagocytosis (GO:0006909)

1.17E-02

cellular process (GO:0009987)

2.25E-04

protein metabolic process (GO:0019538)

1.44E-02

chromatin assembly (GO:0031497)

1.34E-02

response to biotic stimulus (GO:0009607)

1.56E-02

chromatin organization (GO:0006325)

2.22E-02

RNA metabolic process (GO:0016070)

3.60E-02

chromosome segregation (GO:0007059)

2.17E-04

rRNA metabolic process (GO:0016072)

4.29E-02

cytoskeleton organization (GO:0007010)

4.22E-04

1.09E-11

DNA metabolic process (GO:0006259)

5.53E-09

sensory perception (GO:0007600)
sensory perception of chemical stimulus
(GO:0007606)

DNA recombination (GO:0006310)

1.12E-02

3.44E-12

DNA repair (GO:0006281)

1.73E-04

sensory perception of smell (GO:0007608)
single-multicellular organism process
(GO:0044707)

DNA replication (GO:0006260)
I-kappaB kinase/NF-kappaB cascade
(GO:0007249)

3.77E-07

system process (GO:0003008)

1.99E-06

4.39E-03

translation (GO:0006412)

6.14E-03

immune system process (GO:0002376)
intracellular signal transduction
(GO:0035556)

4.81E-03

tRNA metabolic process (GO:0006399)

9.60E-03

1.71E-03

Unclassified (UNCLASSIFIED)

2.48E-04

locomotion (GO:0040011)

5.03E-03

MAPK cascade (GO:0000165)

4.22E-02

metabolic process (GO:0008152)

1.34E-02

mitosis (GO:0007067)
negative regulation of apoptotic process
(GO:0043066)
nitrogen compound metabolic process
(GO:0006807)
nucleobase-containing compound metabolic
process (GO:0006139)

4.37E-02

organelle organization (GO:0006996)
phosphate-containing compound metabolic
process (GO:0006796)

4.73E-03

primary metabolic process (GO:0044238)

3.02E-02

1.77E-02
4.51E-02
1.44E-03

2.83E-03
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6.39E-04

3.27E-02

1.88E-05

3.30E-16

2.21E-05

protein localization (GO:0008104)
pyrimidine nucleobase metabolic process
(GO:0006206)
regulation of catalytic activity
(GO:0050790)
regulation of molecular function
(GO:0065009)
regulation of nucleobase-containing
compound metabolic process (GO:0019219)
regulation of transcription from RNA
polymerase II promoter (GO:0006357)

3.58E-02

response to abiotic stimulus (GO:0009628)

3.56E-02

response to external stimulus (GO:0009605)
response to interferon-gamma
(GO:0034341)

3.35E-02

response to stress (GO:0006950)

1.16E-02

4.25E-02
1.89E-02
2.54E-02
3.98E-02
2.43E-02

3.32E-03
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Supplementary Table 4.3: Significant biological processes in HPV(-) OPSCC, through initial
identification of significantly dysregulated miRNAs and subsequent targets
Overrepresented Processes

Underrepresented Processes

Process Name (GO Number)

P-value

Process Name (GO Number)

P-value

anion transport (GO:0006820)
cellular component morphogenesis
(GO:0032989)
cellular component movement
(GO:0006928)
cellular component organization
(GO:0016043)
cellular component organization or
biogenesis (GO:0071840)
cellular process (GO:0009987)

3.00E-02

gamete generation (GO:0007276)

4.32E-02

9.32E-10

immune response (GO:0006955)

1.54E-03

chromosome segregation (GO:0007059)
developmental process (GO:0032502)

3.36E-02

gluconeogenesis (GO:0006094)

3.04E-02

intracellular protein transport (GO:0006886)

1.29E-03

ion transport (GO:0006811)

1.21E-02

localization (GO:0051179)

7.59E-05

locomotion (GO:0040011)

2.18E-03

mesoderm development (GO:0007498)

2.55E-03

muscle organ development (GO:0007517)

3.31E-02

nuclear transport (GO:0051169)

4.51E-02

pentose-phosphate shunt (GO:0006098)
polysaccharide metabolic process
(GO:0005976)
protein targeting (GO:0006605)

1.25E-02

protein transport (GO:0015031)
regulation of carbohydrate metabolic
process (GO:0006109)
rRNA metabolic process (GO:0016072)

1.83E-03

secondary metabolic process (GO:0019748)

6.18E-03

transport (GO:0006810)

2.93E-04

2.15E-06
4.29E-06

regulation of nucleobase-containing
compound metabolic process (GO:0019219)
regulation of transcription from RNA
polymerase II promoter (GO:0006357)

1.90E-02
3.33E-02

1.38E-07

reproduction (GO:0000003)

1.30E-02

4.89E-06

response to stimulus (GO:0050896)

1.57E-02

1.31E-02

sensory perception (GO:0007600)
sensory perception of chemical stimulus
(GO:0007606)
sensory perception of smell (GO:0007608)
Unclassified (UNCLASSIFIED)

4.33E-02

1.83E-02
4.69E-02

4.32E-03
2.90E-02
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4.01E-03
2.47E-02
6.04E-04

Supplementary Table 4.4: Significant biological processes in HPV(-) CESC, through initial
identification of significantly dysregulated miRNAs and subsequent targets
Overrepresented Processes
Process Name (GO Number)

Underrepresented Processes
P-value

biosynthetic process (GO:0009058)
cellular amino acid metabolic process
(GO:0006520)
cellular component biogenesis
(GO:0044085)
cellular component organization or
biogenesis (GO:0071840)
cellular protein modification process
(GO:0006464)

2.61E-04

Process Name (GO Number)
anatomical structure morphogenesis
(GO:0009653)

5.32E-03

B cell mediated immunity (GO:0019724)

5.14E-03

4.24E-06

biological regulation (GO:0065007)

1.28E-04

2.85E-03

cell communication (GO:0007154)

5.92E-05

2.69E-02

6.38E-03

metabolic process (GO:0008152)

8.60E-08

cell differentiation (GO:0030154)
cell surface receptor signaling pathway
(GO:0007166)

mitochondrial transport (GO:0006839)

5.25E-03

cell-cell signaling (GO:0007267)

1.09E-05

mitochondrion organization (GO:0007005)
nitrogen compound metabolic process
(GO:0006807)
nucleobase-containing compound metabolic
process (GO:0006139)

7.35E-04

complement activation (GO:0006956)
cytokine-mediated signaling pathway
(GO:0019221)
defense response to bacterium
(GO:0042742)

3.73E-02

organelle organization (GO:0006996)

1.17E-03

1.69E-02

oxidative phosphorylation (GO:0006119)
porphyrin-containing compound metabolic
process (GO:0006778)

1.19E-02

developmental process (GO:0032502)
G-protein coupled receptor signaling
pathway (GO:0007186)

3.88E-02

immune response (GO:0006955)

1.07E-05

primary metabolic process (GO:0044238)

4.39E-07

1.11E-02

protein acetylation (GO:0006473)

2.13E-02

immune system process (GO:0002376)
intracellular signal transduction
(GO:0035556)

protein metabolic process (GO:0019538)
respiratory electron transport chain
(GO:0022904)

2.76E-07

4.28E-02

4.99E-02

macrophage activation (GO:0042116)
multicellular organismal process
(GO:0032501)

RNA metabolic process (GO:0016070)

1.12E-03

muscle organ development (GO:0007517)

4.56E-02

rRNA metabolic process (GO:0016072)

9.50E-05

nervous system development (GO:0007399)

4.51E-05

translation (GO:0006412)
tRNA aminoacylation for protein translation
(GO:0006418)

6.34E-13

8.23E-08

4.23E-05

neurological system process (GO:0050877)
regulation of biological process
(GO:0050789)

tRNA metabolic process (GO:0006399)

1.08E-03

response to biotic stimulus (GO:0009607)

1.05E-02

response to stimulus (GO:0050896)

1.76E-07

sensory perception (GO:0007600)
sensory perception of chemical stimulus
(GO:0007606)

6.72E-06

sensory perception of smell (GO:0007608)

3.82E-04

signal transduction (GO:0007165)
single-multicellular organism process
(GO:0044707)

7.25E-05

synaptic transmission (GO:0007268)

6.12E-04

system development (GO:0048731)

4.36E-05

system process (GO:0003008)

9.43E-08

2.14E-02
7.53E-03
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P-value
4.26E-02

1.04E-03

3.43E-02
2.99E-02

4.43E-03

4.44E-02

2.72E-09

1.35E-04

8.01E-06

3.95E-09

Supplementary Table 4.5: Significant biological processes in HPV(+) OPSCC, through initial
identification of significantly dysregulated genes
Overrepresented Processes

Underrepresented Processes

Process Name (GO Number)

P-value

apoptotic process (GO:0006915)

2.26E-02

biosynthetic process (GO:0009058)

9.61E-03

cell communication (GO:0007154)

3.46E-02

cell death (GO:0008219)

1.56E-02

cellular defense response (GO:0006968)

2.98E-02

cellular process (GO:0009987)

2.07E-03

cytokine-mediated signaling pathway
(GO:0019221)
death (GO:0016265)

Process Name (GO Number)
multicellular organismal process
(GO:0032501)
single-multicellular organism process
(GO:0044707)
anatomical structure morphogenesis
(GO:0009653)
biological regulation (GO:0065007)

P-value

cell communication (GO:0007154)
cell surface receptor signaling pathway
(GO:0007166)

6.93E-03

3.13E-02

cell-cell signaling (GO:0007267)

3.74E-02

3.02E-07
3.22E-05
9.70E-04
4.86E-03

2.51E-02

1.56E-02

developmental process (GO:0032502)

3.97E-02

developmental process (GO:0032502)

1.61E-02

ectoderm development (GO:0007398)

4.54E-02

endoderm development (GO:0007492)

4.35E-03

hemopoiesis (GO:0030097)
I-kappaB kinase/NF-kappaB cascade
(GO:0007249)
immune response (GO:0006955)

1.91E-02

immune system process (GO:0002376)

3.10E-02

intracellular protein transport (GO:0006886)

3.48E-03

JNK cascade (GO:0007254)

1.96E-04

macrophage activation (GO:0042116)

2.29E-02

MAPK cascade (GO:0000165)

4.94E-02

metabolic process (GO:0008152)

4.71E-02

mitosis (GO:0007067)
negative regulation of apoptotic process
(GO:0043066)
phospholipid metabolic process
(GO:0006644)
protein localization (GO:0008104)

3.59E-02

protein transport (GO:0015031)

3.05E-03

proteolysis (GO:0006508)
pyrimidine nucleobase metabolic process
(GO:0006206)
regulation of sequence-specific DNA
binding transcription factor activity
(GO:0051090)
response to interferon-gamma
(GO:0034341)

4.83E-02

7.30E-04
1.33E-02

3.16E-02
8.08E-03
4.21E-02

1.96E-02
2.33E-02
1.01E-04
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Supplementary Table 4.6: Significant biological processes in HPV(+) CESC, through initial
identification of significantly dysregulated genes
Overrepresented Processes

Underrepresented Processes

Process Name (GO Number)
antigen processing and presentation
(GO:0019882)
antigen processing and presentation of
peptide or polysaccharide antigen via MHC
class II (GO:0002504)

P-value

Process Name (GO Number)

P-value

1.02E-02

cell recognition (GO:0008037)

4.20E-04

2.60E-02

complement activation (GO:0006956)

1.80E-02

biological adhesion (GO:0022610)

5.47E-03

catabolic process (GO:0009056)

4.41E-02

cell adhesion (GO:0007155)

5.47E-03

cell cycle (GO:0007049)

1.34E-05

cell proliferation (GO:0008283)

defense response to bacterium
(GO:0042742)
gamete generation (GO:0007276)

5.68E-04
3.98E-02
3.13E-02

3.50E-02

mitochondrion organization (GO:0007005)
multicellular organismal process
(GO:0032501)
muscle organ development (GO:0007517)

cell-matrix adhesion (GO:0007160)
cellular component morphogenesis
(GO:0032989)
cellular component movement
(GO:0006928)
cellular component organization
(GO:0016043)
cellular component organization or
biogenesis (GO:0071840)
cellular defense response (GO:0006968)

4.38E-02

neurological system process (GO:0050877)

6.59E-05

7.20E-04

oxidative phosphorylation (GO:0006119)

2.31E-02

4.87E-03

phagocytosis (GO:0006909)

1.15E-02

9.28E-04

protein folding (GO:0006457)

3.39E-02

9.55E-03

protein metabolic process (GO:0019538)

2.23E-02

6.25E-03

reproduction (GO:0000003)

4.45E-02

cellular process (GO:0009987)

6.05E-04

response to biotic stimulus (GO:0009607)

2.95E-02

chromosome segregation (GO:0007059)
cytokine-mediated signaling pathway
(GO:0019221)

3.39E-04

RNA metabolic process (GO:0016070)

2.63E-02

3.17E-02

sensory perception (GO:0007600)

2.85E-09

cytoskeleton organization (GO:0007010)

2.46E-04

DNA metabolic process (GO:0006259)

1.31E-06

DNA recombination (GO:0006310)

9.02E-03

DNA repair (GO:0006281)

2.41E-04

sensory perception of chemical stimulus
(GO:0007606)
sensory perception of smell (GO:0007608)
single-multicellular organism process
(GO:0044707)
system process (GO:0003008)

DNA replication (GO:0006260)

9.62E-05

translation (GO:0006412)

2.69E-03

ectoderm development (GO:0007398)

2.86E-02

tRNA metabolic process (GO:0006399)

3.09E-02

endoderm development (GO:0007492)

3.85E-02

Unclassified (UNCLASSIFIED)

1.02E-03

glycolysis (GO:0006096)

4.97E-02

hemopoiesis (GO:0030097)
I-kappaB kinase/NF-kappaB cascade
(GO:0007249)
immune system process (GO:0002376)
intracellular signal transduction
(GO:0035556)
locomotion (GO:0040011)

3.71E-02

MAPK cascade (GO:0000165)

2.73E-02

metabolic process (GO:0008152)

2.73E-02

mitosis (GO:0007067)
negative regulation of apoptotic process
(GO:0043066)

4.73E-02

2.86E-03
1.40E-02
7.80E-04
5.76E-03

2.59E-02
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2.36E-04
3.01E-02

1.64E-13
2.48E-10
3.61E-04
9.41E-05

nervous system development (GO:0007399)
nucleobase-containing compound metabolic
process (GO:0006139)
organelle organization (GO:0006996)
phosphate-containing compound metabolic
process (GO:0006796)
protein localization (GO:0008104)
pyrimidine nucleobase metabolic process
(GO:0006206)
regulation of nucleobase-containing
compound metabolic process (GO:0019219)
regulation of transcription from RNA
polymerase II promoter (GO:0006357)
response to abiotic stimulus (GO:0009628)

3.41E-02

response to external stimulus (GO:0009605)
response to interferon-gamma
(GO:0034341)
response to stress (GO:0006950)

2.97E-02

6.45E-03
2.77E-03
4.57E-03
4.47E-02
4.60E-02
4.70E-02
1.28E-02
3.44E-02

7.20E-04
3.88E-02
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Supplementary Table 4.7: Significant biological processes in HPV(-) OPSCC, through initial
identification of significantly dysregulated genes
Overrepresented Processes

Underrepresented Processes

Process Name (GO Number)

P-value

Process Name (GO Number)
multicellular organismal process
(GO:0032501)
single-multicellular organism process
(GO:0044707)
anatomical structure morphogenesis
(GO:0009653)

P-value

biosynthetic process (GO:0009058)

6.28E-03

catabolic process (GO:0009056)

3.73E-04

7.68E-03

biological regulation (GO:0065007)

5.58E-03

7.83E-10

cell communication (GO:0007154)

6.49E-04

1.92E-02

cell surface receptor signaling pathway
(GO:0007166)

7.84E-03

3.54E-06

cell-cell signaling (GO:0007267)

6.03E-03

6.03E-03

developmental process (GO:0032502)

4.11E-03

2.23E-02

ectoderm development (GO:0007398)

1.26E-02

coenzyme metabolic process (GO:0006732)

1.06E-02

G-protein coupled receptor signaling
pathway (GO:0007186)

2.03E-02

generation of precursor metabolites and
energy (GO:0006091)

1.27E-04

immune response (GO:0006955)

6.43E-04

glycolysis (GO:0006096)

3.08E-03

metabolic process (GO:0008152)

7.42E-08

intracellular signal transduction
(GO:0035556)
mesoderm development (GO:0007498)

mitochondrial transport (GO:0006839)

9.70E-03

muscle organ development (GO:0007517)

1.71E-02

mitochondrion organization (GO:0007005)
nitrogen compound metabolic process
(GO:0006807)

1.42E-03

8.61E-05

nuclear transport (GO:0051169)

4.99E-04

neurological system process (GO:0050877)
regulation of biological process
(GO:0050789)
regulation of nucleobase-containing
compound metabolic process (GO:0019219)
regulation of phosphate metabolic process
(GO:0019220)

1.77E-02

response to stimulus (GO:0050896)

6.47E-05

2.89E-03

2.10E-05

cellular amino acid catabolic process
(GO:0009063)
cellular amino acid metabolic process
(GO:0006520)
cellular component biogenesis
(GO:0044085)
cellular component organization
(GO:0016043)
cellular component organization or
biogenesis (GO:0071840)
cellular process (GO:0009987)
cellular protein modification process
(GO:0006464)

nucleobase-containing compound metabolic
process (GO:0006139)
nucleobase-containing compound transport
(GO:0015931)
organelle organization (GO:0006996)
phosphate-containing compound metabolic
process (GO:0006796)
primary metabolic process (GO:0044238)

1.69E-02

4.79E-04

1.77E-03

6.57E-06
8.26E-06
4.40E-02

1.78E-02
6.93E-03

9.29E-03
1.87E-02
2.82E-02

1.29E-07

sensory perception (GO:0007600)
sensory perception of chemical stimulus
(GO:0007606)
sensory perception of smell (GO:0007608)

protein complex assembly (GO:0006461)

7.60E-03

signal transduction (GO:0007165)

3.01E-03

protein complex biogenesis (GO:0070271)

7.87E-03

skeletal system development (GO:0001501)

4.63E-02

protein folding (GO:0006457)

2.43E-02

system development (GO:0048731)

4.50E-03

protein metabolic process (GO:0019538)

4.56E-06

system process (GO:0003008)

2.19E-05

protein methylation (GO:0006479)

1.57E-02

Unclassified (UNCLASSIFIED)

4.79E-03

protein targeting (GO:0006605)

1.45E-03

regulation of translation (GO:0006417)
respiratory electron transport chain
(GO:0022904)
RNA catabolic process (GO:0006401)

2.77E-03

RNA metabolic process (GO:0016070)

6.67E-07

1.33E-02

1.45E-02
1.90E-02
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5.99E-04
6.89E-03

rRNA metabolic process (GO:0016072)

4.54E-06

translation (GO:0006412)

7.88E-06

tricarboxylic acid cycle (GO:0006099)
tRNA aminoacylation for protein translation
(GO:0006418)
tRNA metabolic process (GO:0006399)

1.08E-02
4.41E-02
2.82E-05

137

Supplementary Table 4.8: Significant biological processes in HPV(-) CESC, through initial
identification of significantly dysregulated genes
Overrepresented Processes

Underrepresented Processes

Process Name (GO Number)
cellular component biogenesis
(GO:0044085)
metabolic process (GO:0008152)

P-value

Process Name (GO Number)

P-value

2.81E-02

B cell mediated immunity (GO:0019724)

2.76E-02

1.24E-04

biological regulation (GO:0065007)

2.27E-02

mitochondrion organization (GO:0007005)
nucleobase-containing compound metabolic
process (GO:0006139)

1.00E-02

cell communication (GO:0007154)

4.75E-04

2.21E-02

cell differentiation (GO:0030154)

3.36E-02

organelle organization (GO:0006996)

2.36E-02

oxidative phosphorylation (GO:0006119)

1.39E-02

primary metabolic process (GO:0044238)

8.46E-05

protein metabolic process (GO:0019538)

4.66E-04

translation (GO:0006412)

7.18E-05

cell surface receptor signaling pathway
(GO:0007166)
cell-cell signaling (GO:0007267)
G-protein coupled receptor signaling
pathway (GO:0007186)
immune response (GO:0006955)

1.30E-03
4.16E-04
1.23E-02
2.97E-04

immune system process (GO:0002376)
multicellular organismal process
(GO:0032501)
nervous system development (GO:0007399)

3.31E-02

neurological system process (GO:0050877)
regulation of biological process
(GO:0050789)
response to biotic stimulus (GO:0009607)

2.83E-05

response to stimulus (GO:0050896)

7.50E-05

sensory perception (GO:0007600)
sensory perception of chemical stimulus
(GO:0007606)
sensory perception of smell (GO:0007608)

7.50E-04

signal transduction (GO:0007165)
single-multicellular organism process
(GO:0044707)
synaptic transmission (GO:0007268)

7.09E-04

system development (GO:0048731)

6.52E-04

system process (GO:0003008)

2.45E-05
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1.02E-05
8.00E-04

1.16E-02
4.49E-02

3.38E-04
4.70E-03

1.29E-05
6.47E-03

Chapter 5: Conclusions
In this dissertation, we set out to identify transcript-based biomarkers in HPV-related
cancers. Human papillomavirus infection is a distinctive biomarker in cancer, due to its dual
roles as a tumorigenic factor, as well as a positive biomarker for patient survival. Consequently,
there is a demand for additional biomarkers to supplement the existing diagnostic role of HPV in
the clinical setting. To do so, we developed a set of comprehensive bioinformatics tools to
identify transcript-based biomarkers from RNA-seq expression data.
We first applied these bioinformatics techniques to HPV-related cancers in the head and
neck and cervix, using data obtained from The Cancer Genome Atlas. In head and neck
squamous cell carcinomas, we identified a novel set of miRNAs associated with overall survival
in subtypes based on tumor source site; these miRNA biomarkers were also combined to create
an expression-based survival signature that could accurately distinguish between high- and lowrisk patients. Of note, the oropharyngeal cancer signature was able to differentiate patients based
on risk even within the HPV(+) cohort, which can further the goal of personalized medicine in
the treatment of oropharyngeal cancers. This signature was also validated in an independent
dataset, using a different quantification technique, which indicates the robustness of the miRNA
expression signature and its potential applicability within the clinical setting. When comparing
the miRNA signatures to other subtypes of head and neck cancers, these miRNAs were
determined to be subtype-specific, demonstrating the genomic heterogeneity between tumor
source sites also extends to the miRNome. Consequently, the origin of the tumor should also be
considered when determining course of treatment. This tissue speciation in terms of treatment
modality has been previously observed in cervical cancer, as squamous cell carcinomas have
better prognosis than adenocarcincomas and adenosquamous carcinomas. In spite of the genomic
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variability, we were able to identify four distinct miRNAs related to overall survival that were
prognostic in both squamous cell and adeno-type cervical cancers, and formulate an expressionbased signature that was significant independently of tumor source site. This signature could not
be validated in an independent sample cohort; however, the potential of a subtype-independent
signature in cervical cancer shows that these results should not dissuade further research.
With the head and neck cancer cohort, we demonstrated that the techniques for
identifying significant miRNA biomarkers associated with cancer diagnostic parameters could be
extended beyond HPV-related cancers, as well as beyond survival. We obtained miRNA- and
RNA-sequencing data for 30 different cancer types from TCGA and applied the bioinformatics
pipelines to determine the relevance of miRNA expression to tumor formation, diagnostic
staging parameters, and patient survival. The role of differential miRNA expression in various
tumor types was also explored by combining correlation analysis with target prediction analysis
within different tumor types. In addition to providing the static results of these analyses in a webaccessible database, we created a web server that could produce dynamic results for custom
survival signature analysis and clustering analysis to classify the major cancer types. These tools
are all publicly accessible at the website www.oncomir.org.
The underlying biological role of miRNA biomarkers in HPV-related cancers was then
analyzed through a combination of target and correlation analysis integrated with pathway
analysis. By identifying miRNAs dysregulated between HPV(+) and HPV(-) cohorts and
subsequent targets, it was shown that the oncogenic aspect of HPV was supplemented by the
miRNA-guided regulatory mechanism; HPV(-) tumors also demonstrated overrepresentation of
similar biological pathways associated with tumor growth. However, the pathway analysis also
indicated that HPV(-) tumors significantly disfavored biological processes that may prevent
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metastasis. Such insights can guide further research into reason for poorer prognosis in HPV(-)
tumors.
Through this dissertation, we have highlighted clinical and biological applications of
miRNA biomarkers in cancer. The miRNA-mediated mechanisms for HPV-influenced tumor
formation and survival are still under investigation, but the immediate applicability of miRNA
expression levels in the diagnostic setting have been demonstrated. We have also demonstrated
that the tools for identifying transcript biomarkers are applicable across all cancers, and have
made the results of the analysis publicly available. In summary, tools for transcript biomarker
identification have been developed, broadly applied, and produced actionable results for the
research community at large.
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